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ABSTRACT
DNA-binding proteins play a pivotal role in cell biology. The major class of DNA-binding
proteins are transcription factors (TFs). TFs are central to almost every fundamental cellular
process such as cell development, differentiation, cell growth, and gene expression. They account
for 10% of the genes in eukaryotes. In mammals, more than 700 TFs are identified to be DNAbinding TFs. They bind to the TF binding sites (TFBSs) in the genome and regulate the expression
of their target genes. kRAS is a proto-oncogene with intrinsic GTPase activity, that contributes to
cell proliferation, division, and apoptosis. kRAS mutations are observed in >95% of pancreatic
adenocarcinoma and in 30 % of all human tumors. Pancreatic cancer is the fourth most deadly
cancer, with 5 year survival rate of ~6%. When kRAS is mutated it leads to constitutive activity
and uncontrolled proliferation, which results in increased tumorigenicity and poor prognosis. Other
than mutation, kRAS gene amplification, overexpression, or increased upstream activation is also
observed. Downregulating kRAS expression has shown to halt proliferation and lead to cellular
death in pancreatic cancer models, but to date no small molecule capable of silencing expression
has been described. Moreover, the kRAS promoter region is G-rich and is a hot spot for binding
of TFs. TF binding and function in respect to kRAS transcription, is not yet mapped, leading to a
gap in understanding of kRAS transcriptional regulation. In the current study, our purpose was to:
a) identify and evaluate the function and binding interactions of TF’s on the regulation of kRAS,
with a particular focus on two putative G-quadruplex (G4)-forming regions (herein termed near
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and mid) and the core region from 0 - +50, respective to the transcriptional start site and (b) to
evaluate the effect of novel G4 stabilizing compounds on the kRAS expression. This study
evaluated biological effects in both an isolated system with plasmids in HEK-293 cells by
luciferase assay, and in complex in vitro milieus within pancreatic cancer cell lines by RT-qPCR.
Protein changes were evaluated by western blotting. TF binding to the kRAS promoter was
predicted based on consensus binding sites by online tools, and by direct binding was probed by
Qiagen, and by us using a promoter binding array kit, and DNA pulldown followed by LC-MS/MS.
EMSA was utilized for binding studies and effects on G4 formation and stability profile was
probed by ECD. For the identification of kRAS-G4 interactive molecules we used FRET, ECD,
luciferase assay and RT-qPCR. This mapping of TF binding to the kRAS promoter, and the
demonstration of their function as their transcriptional silencers and activators and identification
of G4-interactive molecules is important piece of the puzzle associated with the kRAS regulation.
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CHAPTER 1. INTRODUCTION
1.1. RAS background and function
The enzymes of RAS superfamily are responsible for signal propagation. This family
consists of over 100 GTP hydrolysis switch proteins (small GTPases) which include the RAS,
Rho, Arf, Ran, and Rab proteins (Wennerberg et al. 2005). The name RAS is derived from RAt
Sarcoma, the model system in which this class of enzymes was first described in 1962 (Harvey et
al. 1964). RAS human homologs as genes important in human cancer were identified by Scolnick
and colleagues (Chang et al. 1982). Structurally these small GTPases resemble the Gα subunit of
the heterotrimeric G proteins (large GTPases), lacking the presence of the Gβ and Gγ subunits as
additional regulators (Hurowitz et al. 2000). RAS protein exists in an inactive form when bound
to GDP, and an active form when bound to GTP. In the active state, the RAS proteins are capable
of engaging multiple effector proteins such as RAF, ERK, PI3K etc. Direct binding of effectors to
RAS enzymes changes their conformation, creating an active state in which downstream signaling
is affected, leading to immediate effects on cellular processes like metabolism and survival and
can influence DNA transcription leading to global cellular outcomes such as altered motility,
growth, and differentiation.
The six identified human RAS proteins (kRAS4A, kRAS4B, nRAS, hRAS, mRAS, and
rRAS) share approximately 85% sequence homology. They differ mainly at the C-terminus in a
string of residues termed the “hypervariable region” responsible for the appropriate localization of
these enzymes (Colicelli et al. 2004). The two kRAS proteins are produced from the same gene as
1

a result of alternative splicing and differ in this hypervariable region. Gamma-phosphate of GTP
interacting at the two switch regions (usually at residues threonine 35 of switch 1 and glycine 60
of switch 2) within the RAS proteins leads to kRAS activation (Milburn et al. 1990). The RAS
proteins undergo self-hydroxylation of their GTP molecule to GDP, inactivating the protein, but
the process is slow and needs to be amplified by additional regulatory proteins such as p120 and
NF2.
1.2. The RAS activation cycle
The RAS proteins are activated in response to the engagement of growth factor receptors.
After the binding of growth factors/ligands to the extracellular domain of the tyrosine kinases
(RTK) receptor, the intracellular region of the receptor undergoes a conformational change and is
phosphorylated on tyrosine residues (Fortini et al. 1990). This phosphorylation promotes binding
of proteins containing SH2 domains to the tyrosine sites. SH2 domain-containing proteins, also
known as adaptor proteins, bind to an activated receptor and activate Guanine Exchange Factors
(GEFs). GEF's interact with the kRAS proteins, the result of which is an exchange of the previously
utilized GDP nucleotide for a GTP, also facilitated because GTP occurs at a ten-fold higher
concentration in the cytosol (Vetter et al. 2001). The kRAS enzyme is thus activated and transduces
intracellular signals through other GTPases and kinases, linking the presence of extracellular
growth factors to intracellular signaling cascades.
SOS1, the most extensively characterized GEF, was first identified as an essential regulator
of Drosophila melanogaster eye development (Simon et al. 1993) and later characterized as an
intracellular messenger for the epithelial growth factor receptor (EGFR) in human cells that was
essential for the neurodevelopmental pathway (Rogge et al. 1991). Later Grb2 was found to
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facilitate the activation of Sos1 by growth factor receptors either by direct binding (Lowenstein et
al. 1992) or through binding to other adaptor proteins which are directly bound to these receptors
such as FRS for FGFR signaling (Kouhara et al. 1997) and IRS to elicit insulin receptor induced
Sos1 activation and the RAS signaling cascade (Skolnik et al. 1993). Additionally, in yeast S.
cerevisiae the RasGEF Cdc25 was found as a link between the adenylate cyclase pathway and
RAS activation (Robinson et al. 1987), and later the mammalian homolog was established (Wei et
al. 1992). The Cdc25 mediated activation of RAS signaling was found to be an important regulator
of early development in murine embryonic cells (Chen et al. 1993).
The kRAS enzymes have an intrinsic rate of hydrolysis thus deactivating the enzyme;
however, this rate is insufficient for appropriate biological control. Later, several RAS-GTPase
activating proteins (RASGAPs), such as p120 and NF2, which bind the kRAS enzymes and
accelerated the rate of hydrolysis of GTP, were discovered (Trahey et al. 1987; Trahey et al. 1988;
Martin et al. 1990). These RasGAPs increase the hydrolysis of GTP bound Ras by binding to the
catalytic site on the RAS and reorienting a water molecule using an arginine residue dubbed the
“arginine finger.” Upon RasGAP binding to RAS this water molecule becomes oriented in a
position favoring a nucleophilic attack on the GTP nucleotide (Resat et al. 2001).
1.3. kRAS in development
Despite considerable homology, the RAS proteins still differ in their functions, most
notably in signaling. kRAS found to be indispensable for normal development in mice (Plowman
et al. 2003). The development of mouse embryos beyond the two-cell stage was halted when they
were injected with a dominant negative kRAS N-17, which abolishes all kRAS signaling.
Knocking out of kRAS4B leads to embryonic lethality, which can be rescued by the introduction
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of alternative kRAS isoforms at the kRAS locus (Potenza et al. 2005). The hematopoietic defects
caused by a dysfunctional microenvironment in the fetal liver led to failure of embryos in gestation
between day 12 and day 14 post-fertilization in kRAS4B deficient mice (Yamauchi et al. 1994).
RASopathies is collective term for growth deformities due to series of inheritable and spontaneous
genetic modifications. These arises from mutations that result in the improper activation of the
RAS pathway and thus may serve as a model for the role of RAS in normal development (Rauen
et al. 2010). Noonan syndrome is the most common RASopathy inheritable disorder, occurring in
1/1000 to 1/2500 individuals in the United States. Activating mutations in SOS1, kRAS, or
inactivating mutations in SHP2, a phosphatase that acts on growth factor regulated pathways,
including RAS is responsible for Noonan syndrome. The sites of these activating mutations in
kRAS are different than those seem in human tumors (Schubbert et al. 2006). An extensive set of
developmental problems including facial dysmorphism, skeletal defects, blood defects, heart
problems, neurological disorders, and dwarfism are observed in these patients due to deregulated
kRAS signaling (Tartaglia et al. 2011).
1.4. kRAS signal transduction
kRAS activates seven downstream signaling proteins (Cully & Downward 2008). Detailed
screening in Drosophila melanogaster led to the identification of the first one, RAF1 (Dickson et
al. 1992). This enzyme important for growth and development and is characterized as an activator
of Mek-Erk signal transduction (Kyriakis et al. 1992). Mammals process three RAF isoforms,
ARAF, BRAF, and RAF1. kRAS is known to primarily utilize B-Raf to elicit the Mek-Erk
response, while C-Raf and A-Raf may have evolved to serve both alternative functions including
the inhibition of differentiation and promotion of endocytosis respectively (Kern et al. 2012;
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Nekhoroshkova et al. 2009). The p110 catalytic subunit of PI3K was the next RAS effecter
elucidated (Rodriguez-Viciana et al. 1994). Conversion of the membrane lipid PIP2 to PIP3 is
catalyzed by enzyme PI3K. A specific subset of signaling kinases containing a pleckstrin
homology (PH) domain are recruited by PIP3 to the membrane for activation. Akt is the best
characterized of the PH domain containing proteins in this group which plays an important role in
growth and metabolism. Four isoforms of PI3K exist: alpha, beta, delta and gamma of which alpha
and gamma are confirmed RAS effecters (Ihle & Powis 2010). Mice created with a PI3Kα isoform
which was genetically modified to be deficient in kRAS binding showed embryonic lethality due
to deficient lymphogenesis, displaying a phenotype similar to mice with vascular endothelial
growth factor receptor-3 (VEGFR3) deficiency (Gupta et al. 2007). These proteins allowed the
elucidation of the common structural features of kRAS effectors, the kRAS binding domain or the
RAS association domain (RA), and more effectors began to emerge as a result of massive screening
efforts. The first of these was RALGDS, an activator the RALA and RALB GTPases, which
contains an RA domain (Kikuchi et al. 1994). The Ral GTPases have been demonstrated to play
an important role in endocytosis, the exocyst complex, and nutrient sensing. kRAS also binds
PLCε (Lambert et al. 2002), a phospholipase C isoform with an RA domain responsible for RAS
mediated production of the membrane lipid DAG which results in calcium release and activation
of the PKC signaling cascade (Wing et al. 2003). Finally, kRAS binds Tiam1, an enzyme which
is utilized in integrin signaling (O’Toole et al. 2011) and plays an extensive role in T cell
trafficking through its control of the chemokine and S1P response making it necessary for the
mounting of an appropriate immune response (Gerard et al. 2009).
While these effectors are associated with growth and survival another set of kRAS effecter
RA domain containing proteins associated with apoptosis have been identified; namely the RASSF
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family of enzymes (Vavvas et al. 1998). While the entire set of RASSF proteins have a RA domain,
only a subset is confirmed as kRAS binders. While it is known that the Ras-RASSF complex
engages the pro-apoptotic complex Mst1 many details of this pathway remain to be discovered
(Avruch et al. 2009). The kRAS effectors are shown in (Figure 1-1).
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Figure 1-1. kRAS effector pathways. Validated effecters of Ras signaling and the pathways
activated by each. A majority of Ras effecter pathways promote cellular functions such as
growth, survival, and motility. Unique among these effecters is RASSF1 which is known to
induce apoptosis.
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1.5. kRAS in cancer
The kRAS has been linked with the study of cancers since their initial discovery as the
Kirsten murine sarcoma virus in 1970 (Harvey et al. 1964; Kirsten et al. 1970). In 1982 it was
discovered that transformation was due to the mutations present in kRAS (Chang et al. 1982). In
the US it is estimated that 320,000 individuals will carry mutant kRAS (mut-kRAS) (Jemal et al.
2010). Of the kRAS isoforms, kRAS4B is the most frequently oncogenically activated through
mutation in human cancers. kRAS mutations are observed in cancers that arise from the ectoderm,
such as colorectal cancer (Bos et al. 1987), lung cancer (Rodenhuis et al. 1987) and pancreatic
cancer (Almoguera et al. 1988). kRAS4A, hypothesized to be a tumor suppressor due to its
mediation of apoptosis, is not activated in cancer (Luo et al. 2010).
The kRAS activation by amino acid substitution mutations occurring at codon 12 is most
frequent in human tumors, followed by codons 13 and 61. These mutations result in the enzyme
being “locked” in the GTP-bound state due to an insensitivity to RASGAPs (Trahey et al. 1987).
The wild-type kRAS protein has a glycine, an amino acid lacking a side chain, at both 12 and 13
codons. The introduction of any side chain containing amino acid at the codon 12 or 13 positions,
except proline, serves to increase the activity of kRAS enzyme (Seeburg et al. 1984). The
formation of Van der Waals bonds between RASGAP and kRAS is inhibited by these amino acids
at codon 12, further disrupting the proper orientation of the catalytic glutamine for the γ-phosphate
of GTP found at codon 61 (Wittinghofer et al. 1993). Particular codon and amino acids relate to
specific types of cancer (Prior et al. 2012). The most common mutation for kRAS occurs at residue
12 and is seen in 30% of all cancers (majority being solid malignancies) including lung, pancreatic,
and colon (Lowy & Willumsen 1993; Ostrem & Shokat 2016). In melanoma and myeloid leukemia
mutation of nRAS at position 61 is seen, in breast cancer, mutants of mRAS typically occur on
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residues 22 or 71, and lastly, frequently expressed in bladder cancer, hRAS mutations happen at
either residue 12 or 61 (Ward et al. 2004).
Early studies could not prove kRAS to be driver of tumorigenesis. Activated kRAS resulted
in growth arrest in mouse embryonic fibroblasts only when cell cycle inhibitory checkpoint
proteins were deleted (Serrano et al. 1997). It was later discovered that endogenous levels of active
kRAS in these cells leads to overexpression of key components of the cell cycle and enhanced
proliferation without the deletion of these checkpoints (Tuveson et al. 2004). kRAS has also been
established in multiple systems to be integral in driving other hallmarks of cancer development
and progression, such as the evasion of apoptosis and angiogenesis under hypoxic conditions
(Zeng et al. 2010), cancer invasion into proximal tissues and the establishment of cancer
metastases at distant sites (Campbell et al. 2004).
In human tumors, activating kRAS mutations occur frequently in lung adenocarcinomas,
particularly non-small cell lung cancer (NSCLC), where around 30% of patients have kRAS
mutations (Malumbres et al. 2003) and in colorectal cancer, where approximately 35–40% of
patients have mutations (Bos et al. 1987). In pancreatic ductal adenocarcinomas alone, mutated
kRAS is overexpressed in over 90% of patients (Bailey et al. 2016, cBioPortal for Cancer
Genomics).
1.6. kRAS promoter
The kRAS promoter was first investigated in the 1980s (Jordano et al. 1986; Jordano et al.
1988; Yamamoto et al. 1988), but not much work has been done in the subsequent 40 years to
describe its regulation. The kRAS promoter region responsible for transcriptional initiation and
elongation lie between -510 bp to +50 bp relative to the transcription start site (TSS). This region
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of the kRAS promoter is > 70% rich in guanines (G). The G-rich region of the kRAS promoter
contains 21 bp SV40 repeats, which show resistance to DNAse I (Jonstra et al. 1984) and are a
binding site for Sp1 (Gidoni et al. 1984). Like other housekeeping genes, kRAS contains several
putative Sp1 binding motifs (CCCGCCC), lacks characteristic TATA and CCAAT boxes, and
contains multiple transcriptional initiation sites (Jordano et al. 1986). These data are indicative of
the importance of this region of the kRAS promoter in transcriptional regulation.
1.7. G-quadruplexes (G4’s)
kRAS promoter G-rich regions are clustered around the TSS (Balasubramanian et al. 2011)
and are expected to be the sites for the binding of transcription factors (TFs). Moreover, these Grich regions are capable of forming G-quadruplexes or (G4s). The key component to a G4 structure
is the G-quartet. A G-quartet is composed of four guanine bases that self-assemble to form a square
planar cyclic array. Unlike the hydrogen-bonding of the classical Watson-Crick G-C base pairing
in duplex DNA, the cyclic guanine array is instead held together by eight Hoogsteen hydrogenbonds. By utilizing the N1 and N2 of one face and the O6 and N7 of another, each guanine base
becomes a hydrogen bond donor on one face and a hydrogen bond acceptor on the other and when
two or more G-quartets stack together, they construct the G4 scaffold that may be held together by
loops which are a specific feature of unimolecular and bimolecular G4s. Thus, the definition of a
G4 refers to any four-stranded DNA containing stacked guanine quartets (Parkinson 2006;
Simonsson 2001) are held together by the sugar-phosphate backbone (Huppert 2009). All G4
structures possess a central cavity which is a unique characteristic of a G4 and due to the inwardly
facing O6 guanine carbonyls of the tetrameric arrangement of the four guanine bases, there is an
aggregation of negative charge resulting in electrostatic repulsion that can be stabilized by a locally
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placed cation in the central cavity. For a sequence to form a stable G4, instead of a duplex, it should
have a minimum of four stretches of two or more adjacent guanine nucleotides: G2–5XnG2-5XnG2–
5XnG2–5Xn,

where X is any base and can be up to seven nucleotides (Bochman 2012) (Figure 1-

2).
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Figure 1-2. Assembly of a G-quadruplex (G4) structure. Cyclic arrangement of a Gquartet where each guanine base interacts with its neighbour in Hoogsteen hydrogen
bonding. G-quartets stack on top of one another which are stabilised by a central cation.
Schematic representation of three stacked G-quartets to form the parallel G4 structure
(Adapted from Brooks & Hurley 2010).
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1.8. G4s in promoter
G4-forming motifs are widely dispersed in eukaryotic genomes. They can be found in
immunoglobulin switch regions (Sen & Gilbert 1988; Sen & Glibert 1990), in telomeres
(Blackburn 1991), in the retinoblastoma susceptibility gene (Murchie & Lilley 1992), upstream of
the insulin gene (Bell et al. 1982), and in the promoter regions of many oncogenes and tumor
suppressor genes such as MYC, kRAS, hRAS, nRAS, c-KIT, Bcl-2, pRB, VEGF, HIF-1, hTERT,
and more. In fact, there is at least one example of a G4 forming and acting upon critical genes
responsible for each of the ten hallmarks of cancer (Brooks & Hurley 2010; Cogoi & Xodo 2006;
Morgan & Brooks 2016; Morgan et al. 2016; Onyshchenko et al. 2009; Sun et al. 2014; Phan et
al. 2004; Huang et al. 2012; Bonnal et al. 2003; Ambrus et al. 2006; Aggarwal et al. 2013;
Williamson 1994). With focus on whole genome, putative G4 forming regions promoters have
been shown to cluster 1 kb up-and down-stream of the TSS of approximately 40% of all known
genes (Huppert & Balasubramanian 2007). The core kRAS promoter (-510 to +50) contains three
putative G4-forming regions termed near (-157 to -129), mid (-231 to -179), and far (-278 to -243),
based on their distance from the TSS (Figure 1-3). These G4 forming regions span the two
nuclease hypersensitive regions of the promoter and harbor potential TF binding sites (Quante et
al. 2012; Ishi et al. 1986). Regulatory proteins binding to G-rich DNA regions can have
transcriptional silencing or enhancing effects by recruiting co-proteins or by altering the DNA
topologies within the promoter region. It is notable that while there are three putative G4-forming
regions in the kRAS promoter, only two form inducible structures, and only one has a biological
function (Morgan et al. 2016). Thus, it is likely that while over 40% of promoters may contain
potential G4-forming regions, not all will be stable, form in physiological conditions, or have a
function related to transcription or translation.
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Figure 1-3. kRAS promoter architecture. kRAS promoter extends from (+50 to -510 bp).
The 0 – +50 bp from the TSS is the core promoter region with a role in guiding and initiating
transcription. The complex G/C-rich region of the kRAS promoter downstream to the TSS also
contains three distinct G4 forming regions – termed near, mid, and far.
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1.9. Role of regulatory proteins in transcriptional regulation
Cells recognize and respond to signaling molecules from the extracellular environment.
TFs can be activated due to extracellular ligand binding and subsequent signaling cascades. For
successful transcription by RNA polymerase in eukaryotic cells, diverse arrays of proteins are
crucial. These proteins include general TFs, cofactors, and histones and chromatin remodeling
proteins. TFs are key cellular components that control gene expression, and their activities are
responsible for determining how cells function and respond to their environment. TFs are critical
for the regulation of gene expression. They represent the largest family of proteins in humans, at
nearly 10% of all proteins (Babu et al. 2003).
Several classes of TFs exist including (a) General transcription factors (GTFs) that are
involved in the formation of a preinitiation complex (which are associated with TATA regulatory
elements near TSS’s, such as TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH; (b) upstream TFs
which are proteins that stimulate or repress transcription by binding upstream of the TSS; and (c)
inducible TFs that are similar to upstream TFs, but require activation or inhibition (Myers et al.
2000; Spiegelman et al. 2004).
Typical sequence-specific TFs are composed of a DNA-binding domain (DBD), a
dimerization domain, and a regulatory domain also termed TRD. All TFs contain DBD’s and
proteins that cooperate with them but lack their own DBD’s are termed as transcription cofactors.
Sequence-specific DNA binding TFs are critical in the regulation of gene expression in eukaryotic
cells. In general, they will either increase (enhancers) or decrease (repressors) the rate of
transcription by stabilizing or destabilizing the formation of the preinitiation complex (PIC)
respectively (Latchmann 1997). They impact the stability of the PIC both directly and indirectly
(Semenza 1994). A typical eukaryotic promoter contains one or more copies of a particular cis-

15

regulatory element which is recognized by TFs. Generally, promoters contain cis-regulatory
elements for multiple sequence-specific TFs (Wray et al. 2003). These cis-regulatory modules are
involved in the integration of signals from several TFs, thus giving rise to a broad spectrum of
expression patterns from a single promoter in a context-dependent manner. The activity of several
TFs in various combinations is termed as combinatorial control of transcription. Moreover,
cooperative functioning between multiple copies of the same TF, or between different TF’s could
lead to synergistic effects a phenomenon in which the regulatory effect of multiple factors working
together is greater than the sum of the activities driven by each factor individually on transcription
(Maston et al. 2006). Enhanceosome is a stable nucleoprotein complex formed by cooperating
activators (Thanos & Maniatis 1995) and generates one output to the target promoter by integrating
regulatory information from multiple signaling cascades. These activators seem to cooperate not
in binding, but in activation. In the case of the interferon beta (IFNβ) promoter, the cofactor
CBP/p300 simultaneously contact with multiple activators to elicit a response (Merika et al. 1998).
Similar clusters can also interact to repress transcription (Gowri et al. 2003).
As mentioned above, TFs can bind to other regulator proteins (Co-regulators) to elicit a
response adding yet another layer of regulation to the function of sequence-specific TFs. They are
broadly defined as factors that do not possess DNA-binding properties themselves, but which are
required for the function of sequence-specific TFs (Malik et al. 2000) and are recruited through
protein-protein interactions. Co-factors increase the diversity of responses exhibited by a TF. The
final activity of TF as activators or repressors is dependent on co-regulators (Thomas et al. 2006).
Some examples include chromatin modifiers that work by altering chromatin structure, leaving the
promoter more accessible to the general transcription machinery, and that by linking the TF
directly to the RNA polymerase and the GTFs.
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Sequence-specific TFs often have the ability to form oligomers. Oligomerization leads to
changes in DNA-binding affinity or alterations of sequence specificity (Funnell et al. 2012).
Furthermore, the formation of hetero-dimers represents a form of combinatorial control, as it
allows different combinations of TFs to bind a cis-regulatory element (Funnell et al. 2012; Singh
et al. 1998).
As described, DBD’s recognize the cis-regulatory element within promoters and provide
gene specificity. DNA-binding domains from different families of TFs have distinct but welldefined structures. The classification of TFs based on the structure of their DNA-binding domains
is (Luscombe et al. 2000; Shrivastava et al. 2010):
1) Basic helix-loop-helix (e.g. Helix-loop-helix / leucine zipper factors (bHLH-ZIP), Helixloop-helix factors (bHLH ), and Leucine zipper factors (bZIP))
2) Zinc coordinated DNA binding domains (e.g. diverse Cys4 zinc fingers – GATA factors,
Krüppel factors, Cys4 zinc finger of nuclear receptor type)
3) Helix-turn-helix (e.g. Heat Shock Factors, Ets domain – PU.1, Homeo domain, and Fork
head/winged helix)
4) Beta-scaffold factors (minor groove contact) (e.g. p53, MAD, TATA, CCAAT, NFkappaB, NFAT, STS).
In general, helix-turn-helix or a beta-scaffold factors insert into the major groove of doublestranded DNA to facilitate binding to DBD’s of TF. Usually, the DNA-protein contact spans
approximately 5 bp, with a relatively high affinity (Kd between 10-9 and 10-10 M) and sequencespecificity (Wray et al. 2003). Van der Waals contacts between protein and DNA base-pairs is the
dominant force holding the two together, although contact is also made with the highly negatively
charged sugar-phosphate backbone (Luscombe et al. 2001) (Figure 1-4).
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Figure 1-4. The eukaryotic transcriptional machinery. Transcription by RNA polymerase
II involves the assembly of several factors including TFIIA, TEIIB, TFIID, TFIIE, TFIIF,
TFIIH, co-activators, and activators (sequence-specific transcription factors (TFs)) to form a
pre-initiation complex (PIC). Transcriptional activity is initiated when sequence-specific TFs
bind upstream regulatory cis-elements on the promoter and stimulate PIC formation.
Sequence-specific TFs consist of a DNA-binding domain (DBD) and an activation domain
(AD) that is responsible for protein-protein interaction with components of the PIC, such as
TFIIA or subunits in the mediator complex. The AD can also interact with co-activators or
co-regulators, which in turn can interact with components of the PIC. Adapted from (Maston
et al. 2006).
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1.10.

G4 binding proteins
Several G4 DNA binding proteins from different organisms have been reported. Based on

their function they are classified into five major groups by function: (a) G4 DNA stability
enhancers; (b) non-catalytic G4 DNA destabilizer (c) catalytic G4 DNA destabilizer in an ATPdependent fashion; (d) proteins that promote the formation of G4 DNA formation promoters; (e)
DNA at or adjacently to a G4 domain nucleases (Paramasivam et al. 2009). The mammalian MYC
locus G4 structures are one of the well-studied ones. G-rich region of NHE III1 in the c-MYC
forms G4 structure which regulate transcription (Siddiqui-Jain et al. 2002). In 80% of human
cancer cells, increased levels of MYC expression are observed, and this increase promotes
tumorigenesis. MYC G4 was shown to be a transcriptional repressor. Further, it was shown that
through the binding of nucleolin to G4 structures formed within the NHE III1, act as signaling
elements (Gonzales et al. 2009). Nucleolin is a nucleolar phosphoprotein that is highly expressed
in proliferating cells, known mainly for its role in ribosome biogenesis (Ginisty et al. 1998);
however, nucleolin also functions in chromatin remodeling (Angelov et al. 2006), transcription
(Yang et al. 1994; Grinstein et al. 2007), G4 binding (Dempsey et al. 1999), and apoptosis. It has
been shown that nucleolin binds with higher affinity to the MYC G4 structure over its consensus'sRNA substrate (González et al., 2009). Another hypothesis on nucleolin-G4 binding associated
transcription regulation is that nucleolin-mediated G4 formation in NHE III 1 inhibits MYC
transcription by masking binding sites for MYC transcriptional activators, such as the TF SP1
(Bochman et al. 2012) and cellular nucleic acid-binding protein (CNBP) (Borgognone et al. 2010).
Nucleophosmin a multifunctional protein plays an important role in the pathogenesis of
several human malignancies by interacting with different protein partners including p53, p14arf,
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etc. It specifically recognizes G4 through its intrinsically unfolded C-terminal region (Gallo et al.
2012) which contributes largely to the binding of MYC G4 motif (Scognamiglio et al. 2014).
A nuclear zinc-finger protein PARP-1 is present in approximately one in every 50
nucleosomes and becomes catalytically active upon binding to DNA breaks (Benjamin et al. 1980).
PARP-1 activity is also linked to coordination of chromatin structure and gene expression
(Soldatenkov et al. 2002). PARP-1 was shown to bind DNA hairpins and promoter region in
superhelical DNA (Chasovskikh et al. 2005). PARP-1 binds to intramolecular DNA G4s in vitro
with high affinity and with a stoichiometry of two proteins for one G4 (Soldatenkov et al. 2002).
Using an enzymatic assay, it was shown that PARP-1 gets catalytically activated upon binding to
G4s localized at the c-kit promoter (Soldatenkov et al. 2002).
The most extensively studied tumor suppressor gene is p53. The p53 mutations are
observed in more than 50% of all human tumors, and these mutations inactivate this gene which
plays a critical role in the induction of malignant transformation (Dey et al. 2008). As a TF,
sequence-specific DNA target sites binding is associated with p53. Previously it was shown that
p53 also binds to superhelical DNA and cruciform structures (Palecek et al. 1994; Brazda et al.
2000). Furthermore, p53 binding to bent DNA (Nagaich et al. 1997), DNA bulges, and three- and
four-way junctions (Subramanian et al. 2005), mismatched duplexes, cruciform structures
(Jagelska et al. 2008; Jagelska et al. 2010; Coufal et al. 2013), and structurally flexible chromatin
DNA (Kim & Deppert 2003) has been demonstrated. Recently, the mutant p53 protein was
reported to bind to G-C rich DNA sequences and stabilize G4 structure in vitro (Quante et al.
2012).
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1.11.

kRAS binding proteins
Within the last ten years last decade, the Xodo et al group has focused on one G4-forming

region of the kRAS promoter, G4near (denoted as 32R), in the nuclease hypersensitive element
(NHE) of the kRAS promoter. They have explored the 32R element as an important region in
formation of G4 structure and role in transcription (Cogoi et al. 2016). They utilized pull-down
assays with Panc-1 nuclear extract to identify proteins showing an affinity for the kRAS G4near
region. The proteins identified by LC-MS/MS include poly [ADP-ribose] polymerase 1 (PARP1), ATP-dependent DNA helicase 2, subunit 1 (Ku70) and heterogeneous ribonucleoprotein A1
(hnRNP A1) (Cogoi et al. 2008). hnRNP A1 was selected for further study due to its role in altering
G4 profiles in other promoters (Xodo et al. 2009; Zhang et al. 2006). hnRNP A1 is a member of
the heterogeneous ribonucleoprotein family found in abundance in the nuclei of actively growing
mammalian cells (Dreyfuss et al. 1993; McAfee et al. 1997). There are two highly conserved RNA
recognition motifs at the N-terminus and a glycine-rich domain at the C-terminus (Cobianchi et al.
1986; Shamoo et al. 1994) of all the proteins members of the hnRNP family. It was previously
reported that hnRNP A1 interacts with the kRAS promoter and destabilizes the 32R G4 structure
formed by the GA-element (Cogoi et al. 2009).
The Xodo lab also focused on the MAZ protein and showed that the murine analog of 32R
binds to MAZ (myc-associated zinc-finger), a zinc-finger factor that activates transcription whose
consensus sequence is GGG(A/C)GG (Parks et al. 1996, Cogoi et al. 2010). Both MAZ and PARP1 recognize parallel G4 conformation adopted by the G4-forming element and activate kRAS
promoter, which may be a key in recruiting these proteins to the promoter (Soldatenkov et al. 2008;
Cogoi et al. 2013). Both the murine and the human G4near sequences show a 70% homology, and
the human sequence contains two MAZ-binding sites- GGGCGG and GGGAGG at the 5′- and 3′-
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ends. In human pancreatic cancer cells they observed that when MAZ was overexpressed, kRAS
transcription was upregulated 3.5-fold as compared to the controls (cells treated with a nonspecific plasmid). When MAZ was downregulated (to 10% of control), kRAS transcription was
downregulated by 60% (Cogoi et al. 2013). Notable work in our lab with the whole kRAS promoter
emphasized that it is not the G4near, but G4mid region, which might effects kRAS transcription
(Morgan et al. 2016) and proteins regulating this region are not known.
In light of these different regions and their role in kRAS transcription, there is a need for
extensive exploration of the kRAS transcriptional machinery. There is currently a knowledge gap
about the TFs binding to the kRAS promoter, particularly to different DNA topologies, and their
role in kRAS expression. The long-term goal of this study is to define the endogenous regulation
of kRAS transcription. The first step to achieving that purpose is to examine the binding of TFs to
various DNA regions and topologies within the kRAS promoter, as well as to elucidate the
biological consequence of their binding on transcription. Our central hypothesis is that the TFs
bind to the kRAS G-rich and core promoter regions to modulate expression. G-rich binding
proteins mediate changes in the topology of the kRAS promoter DNA leading to altered
expression. To address our central hypothesis, we will:
1. Identify and examine the TFs and their protein: DNA interactions within the kRAS
promoter.
2. Determine the biological role of regulatory proteins binding to the kRAS promoter.
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Overview of dissertation
This work describes the identification of TFs that bind to kRAS promoter and demonstrates
the functional outcome of TF-kRAS promoter interactions. Chapter 1 gives an introduction about
the thesis research and some relevant background. In Chapter 2, we discuss materials and methods
employed for the studies mentioned in the thesis. After that in Chapter 3 we identify the TFs based
on online putative binding by using PROMO tool, which were subjective to biological evaluation
by dual luciferase assay and RT-qPCR. Chapter 4 is focused on global binding of TFs as
determined by actual binding studies utilizing promoter-TF array kit and Oligo-nuclear extract
pulldown followed by LC-MS/MS. In Chapter 5 we tried to identify kRAS G4mid interacting
compounds which were synthesized by our collaborator. Finally, conclusion and future directions
for this project are described in Chapter 6.
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CHAPTER 2. MATERIALS & METHODS
2.1. Reagents
All oligonucleotides (Table 1) were purchased from Operon (Huntsville, AL).
Acrylamide/bisacrylamide (29:1) solution and ammonium persulfate were purchased from BioRad laboratories (Hercules, CA), and 4,5,6,7-Tetrabromobenzotriazole (TBB) was obtained from
Fisher Scientific (Pittsburgh, PA). MAZ, Sp1, E2F-1, AP-2, PPAR-γ, nucleolin, and YBX-1
plasmids were purchased from Addgene (Cambridge, MA). pGL4.17 plasmid (Empty vector, EV)
and dual luciferase assay kits were acquired from Promega (Madison, WI). All other chemicals,
unless otherwise noted, were purchased from Sigma-Aldrich (St. Louis, MO).
2.2. Putative Binding: Computational Studies
TRANSFAC is a repository that contains data on TFs, their experimentally proven
binding sites, and regulated genes. The online tool PROMO predicts DNA:protein interaction
using the TFBS predicted in TRANSFAC database to construct specific binding site weight
matrices for TFBS prediction (Messeguer et al. 2002). The PROMO algorithm can be accessed
at: http://alggen.lsi.upc.es/cgibin/promo_v3/promo/promo.cgi?dirDB=TF_8.3&calledBy=alggen.
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Table 2-1. List of all oligonucleotides sequences.
5’-3’ sequence
ATTTTCCTAGGCGGCGGCCGCGGCGGCGGAGGCAGCGG
CGGCGGCAGTGGCG
Core complement
CGCCACTGCCGCCGCCGCTGCTGCCTCCGCCGCCGCGGC
CGCCGCCTAGGAAAAT
Biotin-kRAS core
[Biotin~5]ATTTTCCTAGGCGGCGGCCGCGGCGGCGGAGG
CAGCAGCGGCGGCGGCAGTGGG
kRAS G4near
AGGGCGGTGTGGGAAGAGGGAAGAGGGGGAGG
kRAS G4near complement CCTCCCCCTCTTCCCTCTTCCCACACCGCCCTC
Biotin-kRAS G4Near
[Biotin~5]GAGGGCGGTGTGGGAAGAGGGAAGAGGGGGA
GTTTTT
kRAS G4mid
CGGGGAGAAGGAGGGGGCCGGGCCGGGCCGGCGGGGG
AGGAGCGGGGGCCGGGC
kRAS G4mid complement GCCCGGCCCCCGCTCCTCCCCCGCCGGCCCGGCCCGGCC
CCCTCCTTCTCCCCG
Biotin-kRAS G4Mid
[Biotin~5]GCGGGGAGAAGGAGGGGGCCGGGCCGGGCCG
GCGGGGGAGGAGCGGGGGCCGGGCCTTTTT
kRAS G4far
AAGGGGTGGCTGGGGCGGTCTAGGGTGGCGAGCCGGGC
Name
kRAS core
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2.3. Cell Culture
The pancreatic cancer cell lines, MiaPaCa-2 (G12C mutant kRAS), Panc-1 (G12D mutant
kRAS), and AsPc-1 (G12D mutant kRAS), and the non-cancerous HEK-293 cells, were obtained
from ATCC (Manassas, VA). They were maintained in exponential growth in a 37 °C incubator
with a humid environment maintained with 5% CO2 in Dulbecco's Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum (GIBCO) and 1% Penicillin-Streptomycin.
2.4. Transfection and Luciferase Assay
HEK-293 cells were plated at 4×104 in 24 well plates and allowed to attach overnight
before transfection with MAZ or Sp1 or E2F-1 or AP-2 or PPAR-γ or nucleolin or YBX-1
expression plasmids (0, 250, 500, or 1000 ng), 62.5 ng of Renilla luciferase plasmid, and 125 ng
of empty vector (promoter-less) or kRAS promoter (Morgan et al. 2016) luciferase. For MAZ and
Sp1 combination studies, cells were transfected with 500 ng of both the plasmids alone or with the
renilla and firefly plasmids listed above. After 48 hrs, cells were washed with PBS, lysed with
passive lysis buffer, and luciferase expression extrapolated from the firefly and renilla luciferase
activities using the dual luciferase assay kit (Promega, Madison, WI); light output was measured
with a Lumat LB9507 luminometer. Relative luciferase units (RLU, firefly:renilla) were
normalized to no protein expression plasmid, and again to correlative protein-induced-expression
changes in EV, to assess fold changes in kRAS promoter activity. Experiments were run in
triplicate with internal technical duplicates; one-way ANOVA with post-hoc Tukey analysis was
used to determine statistical significance.

26

2.5. Quantitative Real-Time PCR (RT-qPCR)
The Panc-1, MiaPaca-2, and AsPc-1 cells were plated in 12-well plates at a concentration
of 1×105 cells per well for MiaPaCa-2 and Panc-1, and at 2x105 cells per well for AsPc-1 in 1 mL
of media, and were allowed to attach overnight. The following day, the cells were transfected with
increasing concentration of MAZ, Sp1, E2F-1, AP-2, PPAR-γ, nucleolin, or YBX-1 plasmids or
the combination of MAZ and Sp1. 48 hr later, RNA was harvested from the cells using the Thermo
Scientific GeneJet RNA Purification kit (Fisher Scientific); the yield and quality was determined
by NanoDrop 2000, and only samples with 260/230 values >2 were used for further analysis. We
used 500 ng of RNA and the Bio-Rad iScript cDNA synthesis kit to synthesize cDNA; qPCR was
run on a Bio-Rad CFX Connect real-time PCR detection system using TaqMan primers from ABI
kRAS:

Hs00364284_g1,

GAPDH:

Hs99999905_m1,

MAZ:

Hs00911157_g1,

Sp1:

Hs00916521_m1, E2F-1: Hs00153451_m1, AP-2: Hs01029413_m1, PPAR-γ: Hs00234592_m1,
Nucleolin: Hs: 01066668_m1, and YBX-1: Hs00358903_g1). kRAS, MAZ, Sp1, E2F-1, AP-2,
PPAR-γ, Nucleolin, and YBX-1 mRNA expression were normalized to GAPDH, and to untreated
control by the ΔΔCq method. Experiments were run in triplicate with internal technical duplicates;
one-way ANOVA with post-hoc Tukey analysis was used to determine statistical significance.
2.6. Protein Extraction and Western Blotting
Cells were plated in 12-well plates at a concentration of 1×105 cells per well for MiaPaCa2 and Panc-1, and at 2x105 cells per well for AsPc-1 in 1 mL of media, and were allowed to attach
overnight. The following day, the cells were transfected as described above. 48 hr later, cells were
lysed in RIPA lysis buffer (0.5M Tris-HCl, pH 7.4, 1.5M NaCl, 2.5% deoxycholic acid, 10% NP40, 10mM EDTA) containing 100X Halt protease inhibitor (1 µl) and lysed by vortexing after
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every 5 minutes for 30 minutes; proteins were quantified by the bicinchoninic acid (BCA) assay
(Smith et al. 1985). The resultant proteins were solubilized in 2X Laemmli buffer (4% SDS, 20%
glycerol and 0.125 M Tris–HCl, pH 6.8). Equal amounts (40 µg) of proteins were separated on a
10% SDS–polyacrylamide gel electrophoresis (PAGE) and transferred at 25 V, 2.5 A for 7 minutes
in Trans-Blot® Turbo™ Transfer System (Hercules, CA). The membranes were incubated with a
primary anti-kRAS antibody (diluted 1:1,000, Cell Signaling, cat#3965), anti-MAZ antibody
(diluted 1:500, Active Motif, cat#39936), anti-Sp1 antibody (diluted 1:1,000, Active Motif,
cat#39058), anti-E2F-1 antibody (diluted 1:1,000, Cell Signaling, cat#3742) , and a secondary
rabbit IgG peroxidase-conjugated antibody (1:10,000, Cell Signaling, cat#7074). The β-actin level
in each sample was measured with anti–β-actin antibody (1:10,000, Cell Signaling, cat#3700) and
a mouse IgM peroxidase-conjugated antibody (1:10,000, Cell Signaling, cat#7076). The antibodies
were diluted in 10 mM Tris, pH 7.9, 150 mM NaCl, 0.05% Tween and 5% bovine serum albumin.
The signal was developed by treating the membranes with enhanced chemiluminescence (ECL,
Thermo Fisher Scientific, Rockford, IL) and detected on a ChemiDOC XRS using Quantity One
4.6.5 software (Bio-Rad Laboratories, CA, USA).
2.7. Nuclear Protein Extraction
HEK-293 cells (1x106) were plated in a 150 mm x 25 mm petridish supplied with 6 ml of
complete growth medium (DMEM + 10% Fetal Bovine Serum), and allowed to attach overnight.
When the dish was 70-80% confluent, cells were transfected with 20 µg of MAZ, Sp1, E2F-1, AP2, PPAR-γ, Nucleolin or YBX-1 expression plasmids. After 48 hr, nuclear extraction was
performed according to Thermo Scientific NE-PER Nuclear and Cytoplasmic Extraction Kit
(Waltham, MA). Briefly, cells were harvested with trypsin-EDTA and then centrifuged at 500 × g
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for 5 minutes. After that, the cell pellet was suspended in PBS and was transferred to a 1.5 mL
micro centrifuge tube before pelleting by centrifugation at 500 × g for 2-3 minutes. Ice-cold 500
µl CER I was added to the pellets, the tube was vortex vigorously for 15 seconds and incubated on
ice for 10 minutes. Next, ice-cold 27.5 µl CER II was added to the tube and tube was vortexed for
5 seconds on the highest setting before incubating on ice for 1 minute. The sample was centrifuged
for 5 minutes at 16,000 × g. The cytoplasmic extract was transferred to a new tube and 250 µl of
NER was added to the cell pellet. The tube was vortexed at the highest setting for 15 seconds,
every 10 minutes, for a total of 40 minutes. The tube was centrifuged at 16,000 × g for 10 minutes.
The lysate concentration was measured using the BCA assay kit (Pierce Biotechnology, USA),
against a standard curve generated by serial dilutions of 10mg/ml bovine serum albumin (BSA).
The nuclear fraction was aliquoted in a clean pre-chilled tube and was stored at -80°C until use.
2.8. Electrophoretic Mobility Shift Assay (EMSA)
Biotinylated oligonucleotides (5 μM) of the kRAS-G4 sequences of the near and mid G4forming sequence were heated at 95 °C for 10 min followed by slow cooling to form G4s. The
dsDNA were formed in the thermal cycler by incubating with the complementary strand at 95 oC
for 5 minutes followed by a controlled cooling at -1 oC/ minute to a terminal temperature of 25 oC.
MAZ or SP1 nuclear extract (20 μg) was incubated in 2× binding buffer (40 mM Tris–HCl, pH
7.5, 40 mM NaCl, 40 mM KC1, 10% (w/v) glycerol, 2 mM EDTA, and 2 mM DTT) for 30 minutes
on ice (Sam & Club 2012). The biotin-labeled oligonucleotide of different DNA topologies (ss-,
ds-, or G4-DNA) was added to the mixture and was incubated for 20 minutes at room temperature.
Before loading the samples, 0.25 µl of Eva Green (20X) to visualize DNA and 0.5 µl 6X loading
dye was added to each sample. Samples were loaded on a 0.5% Agarose gel prepared in 0.5 × TBE
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buffer (1.25 mM boric acid, 12.5 mM Tris, 0.25 mM EDTA, pH 8.0). Electrophoresis was in 0.5
× TBE buffer at 100 V for 45 min at room temperature. The gel was visualized under blue light
LED using a FotoDyne Investigator FX Imager.
2.9. Electronic Circular Dichroism (ECD)
Unlabeled oligonucleotides (5 μM) of the kRAS-G4 sequences of the near and mid G4forming sequences were heated at 95 °C for 10 min followed by slow cooling to form G4s. After
2 hr the samples were incubated with either 5% NE or 5% NE from cells transfected with MAZ or
Sp1 protein. Background-corrected ECD spectra were recorded on an Olis DSM-20
Spectrophotometer fitted with a CD 250 Peltier cell holder (Bogart, GA) from 225 to 350 nm with
scanning time as a function of high volts (generally 0.5 – 1 sec per nm). Thermal stability was
determined by collecting full (225-350 nm) over a range of increasing temperatures (20-100 °C,
spectra collected every 10 °C after a 1-minute hold at temperature). TMs were determined by
performing singular value decomposition (SVD) (DeSa & Matheson 2004). All spectra were
baselined for signal contributions from the buffer.
2.10. MTS Cellular Viability Assay
For cellular viability assays, MiaPaCa-2, Panc-1, and AsPc-1 cells were plated at 7,500
-well plate and allowed to attach overnight. The following day, a 10x
stock plate of TBB diluted from 10 mM over a 5-6 log range in 0.5 log steps was made, and 10 μL
of this stock was added to the cell plate, in triplicate such that the highest dose tested was 1 mM;
cells were incubated with compound; wells with no cells served as background after compound
was added for this colorimetric assay. After 48 hr, 20 μL of 3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) + 5% phenazine methosulfate
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(PMS) was added to each well and incubated for 2-4 h before the absorption at 490 nm was
measured on a BioTek Synergy 2 plate reader (Winooski, VT) (Mossman 1983). Background
absorptions were subtracted, and data were normalized to control cells. GraphPad Prism (San
Diego, CA) was used to calculate the IC50 using a non-linear regression model.
2.11. Promoter-Binding Transcription-Factor Profiling Array Assay
To screen for TFs that bind to the kRAS promoter (-510 – +50), the activities of 48 TFs in Panc-1
cells were assayed using a Promoter-Binding TF Profiling Array (Signosis, CA). The assay was
performed as recommended by the manufacturer’s instructions. Briefly, nuclear extract was
isolated from 1x106 Panc-1 cells using a Thermo Scientific NE-PER Nuclear and Cytoplasmic
Extraction Kit (Waltham, MA). The reaction mixture was prepared using 15 μl of the TF binding
buffer, 3 μl of the probe, 10 μg of nuclear extract and 5 μl of the kRAS promoter fragment (510/+50) and was incubated at room temperature for 30 min to allow for the formation of the TFDNA complex. Unbound probes were separated from the complex, while bound probes were
eluted and then hybridized to the plate and incubated overnight at 42°C. Bound probe was detected
using an HRP-streptavidin conjugate incubated with the chemiluminescent substrate.
Luminescence is reported as relative light units (RLUs) on a SpectraMax® M5/M5e Multimode
Plate Reader, (Sunnyvale, California).
2.12. DNA- Pulldown Assay
One mg of nuclear protein extract (0.25 mg/ml), prepared as described (Cogoi et al. 2008),
was incubated for 1 hr at 37 °C with 4 µM biotinylated G4-DNA (annealed with 100 mM KCl) or
biotinylated duplex (G4-biotin annealed with its complementary strand in 100 mM NaCl) in a
solution containing 20 mM Tris-HCl, pH 8, 8% glycerol, 150 mM KCl, 25 ng/ml poly(dI-dC), 1
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mM Na3VO4, 5 mM NaF, 1 mM DTT, and 0.2 mM phenylmethylsulfonyl fluoride. Then 250 μg
of Streptavidin MagneSphere Paramagnetic Particles (Promega) pretreated for 30 min with 0.25
mg/ml BSA were added and incubated for 30 min at 37 °C. Particles were captured with a magnet,
and the proteins were eluted with the buffer containing 0.5 and 1 M NaCl. The eluted proteins
were used for further analysis.
2.13. Sample Preparation
In order to digest the proteins, the proteins were solubilized in Tris buffer, pH 8.0 with 1
mM CaCl2. The proteins were denatured by heat at 95 oC for 20 minutes in the presence of 10 mM
dithiothreitol (DTT). After the solution was cooled to room temperature, 20 mM iodoacetamide
was added and samples were kept at room temperature in dark for 45 minutes. After incubation,
20 mM DTT was added to quench the iodoacetamide followed by sequencing grade trypsin in 1:20
of protease to protein ratio and incubated at 37 oC overnight with rotation.
2.14. Mass Spectrometry
The samples were acidified with 0.1% formic acid, spun briefly and the supernatant was
transferred to sample vials. An Orbitrap Fusion tribid mass spectrometer coupled to an ultimate
3000 HPLC system was used for the nano-LC-MS/MS analysis. The samples were first loaded
onto a trap cartridge containing C18 stationary phase to desalt the samples. After 4 minutes,
samples were loaded onto nano PepMap column (75 µm inner diameter, 150 mm length, particle
size 3 µm). The mobile phase (B) consisted of 100% acetonitrile and 0.1% formic acid. The peptide
separation was achieved with a linear gradient from 0 to 40 % B for 25 min at 0.3 µL/min. The
mass spectrometer was operated at a capillary temperature of 300 oC. The peptides were
fragmented by collision-induced dissociation and the normalized collision energy was set to 35%.
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The MS scan range was m/z 150-2000 and the top 15 peaks were selected in precursor scan for the
data dependent CID fragmentation in each cycle.
2.15. Database Search
The resulting RAW files were searched by Byonic database search engine (version v2.10.5)
against human proteome database (downloaded from Uniprot). Proteins were filtered by log
probability and only proteins that have log probability >5 were considered. False discovery rate
was set at 1%.
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CHAPTER 3. TRANSCRIPTION MAPPING AND FUNCTIONAL ANALYSIS OF THE TFs
TO THE kRAS PROMOTER
3.1. Introduction
kRAS is a GTPase that, upon activation, initiates a cascade leading to enhanced
transcription and cellular proliferation. kRAS proteins can act as signal transducers, converting
upstream extracellular signals to downstream intracellular effects through three important
pathways (RAF serine/threonine kinases, phosphatidyl‐inositol‐3‐kinase (PI3K), and RAS‐like G
proteins RALA and RALB) (reviewed in Shapiro 2002; Wellbrock, Karasarides et al. 2004;
reviewed in Vivanco and Sawyers 2002; reviewed in Katz and McCormick 1997; Ferro and
Trabalzini 2010). The physiologic roles of the above kRAS pathways can be broadly categorized
as mitogenic, anti‐apoptotic, and pro‐cell‐survival. Thus, RAS sits at the apex of a signaling hub
that, if activated to a pathophysiologic extent, could promote cancer. Pancreatic, as well as
colorectal and lung cancers, frequently present with a mutated kRAS protein mediating enhanced
intracellular signaling cascades, as compared to non-tumor tissues (Rall et al. 1996; Grunewald et
al. 1989). In the absence of a mutation, some cancers demonstrate gene amplification and
overexpression of kRAS at the transcriptional and translational level. For example, in esophageal
adenocarcinomas, 40% of the tumors were found to have amplification of the kRAS gene (Galiana
et al. 1995), and in low-grade ovarian serous carcinomas, overexpression of kRAS was responsible
for 41% of active MAPK in tumors (Hsu et al. 2004). Amplifications of kRAS are also noted in
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endometrial and uterine cancers, testicular cancers, and triple negative breast cancers
(cbioportal.com).
kRAS plays a distinctive role in different stages of cancer. Interestingly, several genes
involved in metabolism are identified to be regulated by kRAS (Ying et al. 2012). Additionally, it
was reported that to aid in the maintenance of the tumor cell's redox state, kRAS plays a role in
the regulation of glutamine metabolism (Son et al. 2013). In mice, oncogenic kRAS (G12D) is
required for initiation and maintenance of pancreatic cancer. kRAS leads to extracellular matrix
remodeling by upregulating Hedgehog signaling pathway, fibroblast activation, inflammatory cell
infiltration, and production of enzymes (matrix metalloproteinase 7 (MMP7)). In early stage
PanIN, inactivation of kRAS causes re-differentiation of PanIN cells into acinar cells which leads
to remodeling of the stroma and complete tumor regression. At late stages of PanIN, this reversal
of tumor development is not possible due to addiction of cells to continuous expression of
oncogenic kRAS (Ying et al. 2012; Collins et al. 2012; Collins et al. 2012).
The kRAS promoter was first described in the 1980s (Jordano & Perucho 1986; Jordana &
Perucho 1988; Yamamoto & Perucho 1988); however, little has been done since to describe its
regulation. The kRAS promoter is > 70% rich in guanines (G). Such G-rich regions of DNA are
clustered around the TSS (Balasubramanian et al. 2011) and are known to be the sites for the
binding of TFs. The proteins identified to bind kRAS promoter were poly[ADP-ribose] polymerase
I (PARP-1), ATP-dependent DNA helicase 2 subunit 1 (Ku70) and heterogeneous nuclear
ribonucleoprotein A1 (hnRNP A1). In addition, Myc-associated zinc-finger protein (MAZ) on the
basis of its consensus sequence was predicted to have binding sites on GA element of hRAS and
kRAS promoter. This putative interactions was confirmed by EMSA and chromatin
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immunoprecipitation experiments, and MAZ was established as transcriptional activator of kRAS
(Cogoi et al. 2010; Cogoi et al. 2013; Cogoi et al. 2014).
TFs are critical for the regulation of gene expression (Thomas et al. 2006). They represent
the largest family of proteins in humans at nearly 10% (Babu et al. 2004). TFs are mainly classified
into two types: general and sequence-specific. The general TFs are involved in the transcription of
a large fraction of genes by cooperatively acting with RNA polymerase II (Lee & Young 2000).
The sequence-specific TFs bind to specific subsets of target genes and lead to distinct
comprehensive patterns of gene expression (Kadoonga 2004). TF’s function to recruit cofactors,
RNA polymerase II, and binding enhancer elements to target genes (Lelli et al. 2012; Ong &
Corces 2011; Spitz & Furlong 2012). Multiple TFs regulate transcription from the core promoters
of nearby genes by binding to individual enhancers in cooperative fashion (Panne 2008). This
physical interaction results in looping of the DNA between the core promoters and enhancers
(Krivega & Dean 2012).
The easiest way to determine DNA-TF binding is through in silico methods. The
computational method are used to determine the link of “TF to Transcription factor binding sites
(TFBS)” by predicting/identifying TFBSs on the DNA sequence (Stormo & Zhao 2010). The links
of the form “TFBS-gene” are normally found by looking at the proximity of predicted/identified
TFBS to the gene location. Since TFs are considered to control the key aspects of transcription
initiation and thus have a great impact on the regulation of gene expression, one of the significant
goals in molecular biology has been to understand sequence-specific binding of TFs to DNA.
Important issues that need to be considered when using these approaches for TFBSs prediction are
to minimize false positive rate (over-prediction error) and to minimize false negative rate (underprediction error) (Pickert et al. 1998). The most popular models of the TFBS families are those
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based on position weight matrices (PWMs) of mononucleotides (Stormo 2000). PWM, also known
as position-specific weight matrix (PSWM), is a simple statistical representation of the set of TFBS
motifs. They are the most popular way of representing collections of aligned motifs as PWM, are
relatively simple, and they result in much more accurate models of TFBS families (Stormo 2000).
Models based on Markov chain (Zhou et al. 2005; Ellrott et al. 2002), Hidden Markov Models
(Bailey et al. 1995) and models that use remote dependencies between the positions in TFBSs are
more complex and more sophisticated models for the same purpose. Unfortunately, these models,
while providing some improvements in accuracy over the PWM models, still appear not to be
sufficiently accurate. Two major databases, TRANSFAC (Wingender 1996) and JASPAR
(Sandelin 2004), store many of these experimentally determined TFBSs and their derived PWM
models. The method was also employed to determine the putative binding of the MAZ to the kRAS
promoter (Cogoi et al. 2013). With very few exceptions such as PARP-1, Ku70, and hnRNP A1
identified by pulldown assay (Cogoi et al. 2010) the TF’s regulating the expression of kRAS
remain a mystery.
In addition to serving as TF binding sites, G-rich regions are capable of forming G4's,
which are higher order DNA structures in which guanines Hoogsteen-base pair with each other.
The core kRAS promoter (+50 to -510) contains three putative G4-forming regions termed near (129 to -157), mid (-179 to -231), and far (-243 to -278) based on their distance from the TSS.
Within the kRAS promoter, the G-rich regions putatively serve both as sites for TF binding and
G4 formation. G4 formation and the impact of TF binding and transcriptional regulation in the
promoter region of important oncogenes like MYC, Bcl-2, c-KIT, and VEGF, has been studied
before (Sun et al. 2008; Siddiqui-Jain et al. 2002; Dexheimer et al. 2006; Shirude et al. 2007;
Morgan et al. 2016). Most often, although not always, G4's function to suppress transcription by
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sequestering TF binding sites and are an interest of study for various oncogenic promoters. Several
proteins such as nucleolin, nm23-H2, MAZ, UP1, and Sp1 have been noted to bind to these G-rich
sequences and/or G4 structures and alter the stability profile of G4's (Brooks & Hurley 2009;
Thakur et al. 2009; Paramasivam et al. 2009; Cogoi et al. 2010; Cogoi et al. 2013; Raiber et al.
2012; Piekna-Przybylska et al. 2014). Other than their role in transcription of TATA-less GC-rich
promoters, MAZ (5’-GGGGGAGGGGGG-3’) and Sp1 (5′-(G/T)GGGCGG(G/A)(G/A)(C/T)-3)
are also known to share their consensus binding sequence (Kadonaga et al. 1986; Ashfield et al.
1994). Both of these proteins have been found to have a role in activating transcription and in
binding to alternate DNA (G4) topologies (Her et al. 2003; Cogoi et al. 2013).
With such similarities in consensus binding sites, other regulatory mechanisms of MAZ
and Sp1 have been studied. In particular, studies within the promoter of phenylethanolamine Nmethyltransferase (PNMT) were undertaken to examine general affinity and regulation of these
two TFs. MAZ demonstrated a higher affinity to the PNMT promoter as compared to Sp1 but
demonstrated a lower activation level. For either protein to bind and activate this promoter, both
proteins must be phosphorylated (Her et al. 2003); casein kinase 2 (CK2) mediates this
phosphorylation. Casein kinase 1 and CK2 were the first protein kinases to be discovered (Burnett
& Kennedy 1954). CK2 is an essential protein kinase found ubiquitously in a variety of eukaryotic
tissues and organisms; it is highly conserved from protozoan level (Kikkawa et al. 1992; OleMoyoi et al. 1992; Ospina et al. 1992) and can phosphorylate more than 300 substrates, including
both Sp1 and MAZ (Meggio & Pinna 2003). CK2-mediated phosphorylation of MAZ and Sp1 was
shown to lead to alternative binding of these proteins to the MYC promoter (Figure 3-1). In MAZ,
CK2 phosphorylated serine residue at position 480 in the carboxy-terminal region and resulted in
an increase in the DNA-binding of MAZ to the pyrimidine-rich c-myc NHE (5’-
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TCCTCCCCACCTTCCCCACCCTCCCCACCCTCCCC-3’) which in turn enhanced the MYC
gene transcription (Tsutsui et al. 1999). On the other hand, phosphorylation of the carboxy
terminus of Sp1 by CK2 resulted in a decrease of the DNA-binding activity. (Armstrong et al.
1997).
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Figure 3-1. CK2 phosphorylation of MAZ and Sp1. CK2 phosphorylates MAZ and
Sp1. This leads to altered binding profiles and opposite effects on MYC transcription.
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Globally, the regulatory proteins for the kRAS promoter, and the modulation of various
topologies (single strand (ssDNA), double strand (dsDNA), and G4 DNA), is an untold story,
which needs to be explored further. We hypothesized that regulatory proteins bind to the kRAS
promoter and elicit a response based on their different region binding and affinities. The
hypothesis was investigated by examining binding of MAZ, Sp1, and E2F-1 to the kRAS promoter,
including a consideration of the structural forms of DNA to which the proteins were binding, and
the functional outcome of their binding on kRAS promoter activity. The knowledge of the kRAS
regulation is important for the drug discovery efforts as well as to fill up the puzzle related to
kRAS biology. We aim to gain such knowledge through following aims:
Specific Aim 1. Identify and examine the MAZ, Sp1 and E2F-1 and DNA interactions
within the kRAS promoter.
Specific Aim 2. Determine the biological role of MAZ, Sp1 and E2F-1 binding to the
kRAS promoter.
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3.2. Sp1, MAZ, and E2F-1 Putative binding sequences on kRAS promoter
Select regions of the minimal promoter of kRAS from -510 to +50, in relation to the TSS
(Jordano & Perucho 1986; Jordana & Perucho 1988; Yamamoto & Perucho 1988) were used to
map TF binding sites. Specifically, PROMO online tool was used for identification of putative
TFBS in the kRAS promoter region. In particular, we used the core region (0 – +50), the G4nearforming region (-128 – -160), and the G4mid-forming region (-174 – -226). A number of proteins
mapped to these regions, including E2F-1, p53, WT1, MAZ, and Sp1. Of those, MAZ and Sp1
were of particular interest as they have overlapping consensus sequences that are highly prevalent
in G4-forming regions, both have been shown to bind both dsDNA and G4-DNA, and MAZ has
particularly been linked to the kRAS promoter previously (Cogoi et al. 2013). MAZ binding was
mapped to the G4near-region, in agreement with previous literature, and also had two potential
binding sites within the G4mid-region. For Sp1, we found several binding sites throughout the
kRAS promoter region with approximately two potential binding sites per each of the three regions
of interest. Lastly, for E2F-1 there were four binding sites in the core promoter region from 0 to
+50 bp. (Figure 3-2).
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Figure 3-2. Transcription factors binding sites on the kRAS promoter. The complex Grich region of the kRAS promoter contains three distinct G4 forming regions – termed near,
mid, and far. Several transcription factor binding sites lie within this extensive region, including
a number for the MAZ (three), Sp1 (seven), E2F-1(five), WT1 (two), and P53 (seven).
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3.3. Biological role of MAZ, Sp1, and E2F-1 on kRAS promoter regulation
These putative binding techniques help identify the binding sites between TFs and target
genes. However, many of the binding events are not functionally relevant as they do not result in
a change in target gene expression. Thus, the effects of TF binding target gene expression needs
to be functionally validated. DNA binding proteins can have varying functional outcome,
dependent on context and binding partner (Fry & Farnham 1999). We sought to define the effect
of MAZ and Sp1 on kRAS transcription with two studies. First we analyzed the effect of these
proteins on isolated kRAS promoter in HEK-293 cells by dual luciferase assay, and second we
tested the overexpression of MAZ, Sp1, and E2F-1 on endogenous expression by PCR. For dual
luciferase assay, a promoter-less vector (EV) was included as a control. A luciferase assay was
performed in HEK-293 cells transfected with a luciferase plasmid driven by the kRAS promoter
Full Length (FL) or with EV, in the presence of increasing expression of the MAZ and Sp1
plasmid. In both cases, increasing MAZ and Sp1 expression led to a significant decrease in kRAS
promoter activity, as measured by up to 50% (at 500 ng) (Figure 3-3A). Sp1 induced an even more
marked change, as kRAS promoter activity was decreased by up to 80% at 500 and 1000 ng
respectively (Figure 3-3B). As MAZ and Sp1 are known to share the binding sites, we transfected
them together at 500 ng concentration with the FL kRAS promoter. MAZ and Sp1 combination
abrogated their specific silencing effect and led to significant increase in the kRAS promoter
activity as measured by luciferase expression. The increase was by 270% as compared to control
(Figure 3-3C). Increasing E2F-1 expression led to significant increase in kRAS promoter activity
as measured by up to 60% (at 500 ng) (Figure 3-3D) In MAZ, Sp1, and E2F-1 dose dependent
studies *p< 0.05 (versus control), was determined by one-way ANOVA with Tukey post-hoc
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testing. For the MAZ + Sp1 combination studies *p< 0.05 (versus control) was determined by twotailed Student t-test.
The effects of MAZ, Sp1, and E2F-1 proteins, alone and in combination, on kRAS
expression was also studied in pancreatic cancer cell lines. In particular three cell lines
homozygous for mutant kRAS with varying levels of addiction to the oncogene, MiaPaCa-2
(moderate addiction), Panc-1 (low addiction), and AsPc-1 (high addiction) were transfected with
increasing MAZ, Sp1, E2F-1, and MAZ + Sp1 expression plasmids and the expression of MAZ,
Sp1, E2F-1, and kRAS were monitored at the transcript and protein levels. We noted the basal
levels of MAZ, Sp1, and kRAS in different cell lines. The basal levels of all these transcripts varied
with AsPc-1 showing maximum levels of kRAS, MAZ, and Sp1 followed by Panc-1, with
MiaPaCa-2 showing the lowest level of kRAS (Figure 3-4A). The data from the cell lines with
each TF individually was in accordance with the luciferase findings – kRAS transcription was
significantly decreased by in the presence of MAZ or Sp1, respectively (Figure 3-5A and B,
respectively). On the other hand, E2F-1 showed opposite effects. E2F-1:kRAS promoter
interaction showed significant increase in kRAS mRNA expression (Figure 3-5C). All changes in
mRNA were also examined at the protein level in MiaPaCa-2 cells transfected with 500 ng MAZ
plasmid, 100 ng Sp1 plasmid and 100 ng E2F-1 plasmid. The results concurred with the RT-qPCR
as kRAS decreased with increasing MAZ or Sp1 (Figure 3-5D-E). With E2F-1, increase in kRAS
protein expression was observed as that by RT-qPCR (Figure 3-5F). The panel of cell lines were
also transfected with 500 ng of MAZ and 100 ng of Sp1 plasmid (consistently mediating an
increase in TF transcription by less than 15-fold). The combination of MAZ and Sp1 abrogated
the silencing effect of either protein alone, as observed by either no change in kRAS mRNA, or an
increase in expression (Figure 3-6A); again this finding was in agreement with the plasmid
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findings. Increase in western blot with the MAZ and Sp1 combination was also observed (Figure
3-6B). Collectively these data support that the MAZ and Sp1 individually act as transcriptional
silencer but in combination, the effects are abrogated or even reversed. E2F-1 was classified as a
transcriptional activator of kRAS.
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Figure 3-3. MAZ, Sp1, MAZ +SP1, and E2F-1 effect on kRAS promoter activity. A
luciferase assay was performed in HEK-293 cells transfected with a luciferase plasmid driven
by the kRAS promoter in the presence of increasing MAZ, Sp1, MAZ + Sp1, E2F-1 expression
plasmid. Promoterless (EV) was included as a control. Increased MAZ & Sp1 expression leads
to decreased kRAS promoter activity as measured by fold change in RLU, normalized to the
EV effect. (A, B) The combination of 500 ng of MAZ + Sp1 abrogates the decreased kRAS
promoter activity seen with either protein alone (C). Increased E2F-1 expression leads to
increased kRAS promoter activity as measured by fold change in RLU, normalized to the EV
effect (D). *p< 0.05 (versus control), as determined by one-way ANOVA with Tukey post-hoc
testing. All experiments were performed in a minimum of triplicate.
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Figure 3-4. Basal levels of MAZ, Sp1, E2F-1, and kRAS in pancreatic cancer cell lines. At
Basal level (0 ng) levels of all the proteins were normalized to the MiaPaCa-2 cells. AsPc-1 and
Panc-1 nearly similar levels of all proteins.
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Figure 3-5. kRAS, MAZ, Sp1, and E2F-1 expression change on pancreatic cell lines.
The pancreatic cancer cells MiaPaCa-2, Panc-1, and AsPc-1 were transfected with
increasing MAZ, Sp1, and E2F-1 expression plasmid; the mRNA expression of MAZ,
Sp1, E2F-1, and kRAS were monitored. (A) The MAZ:kRAS promoter interaction in the
pancreatic cell lines showed similar results as luciferase assay. The decrease in mRNA
kRAS expression with increasing MAZ expression. (B) The Sp1:kRAS promoter
interaction in the pancreatic cell lines followed the same pattern as MAZ. (C) The E2F1:kRAS promoter interaction the increase in mRNA kRAS expression with increasing
E2F-1 expression was observed. The protein level by western blot at 500, 250, and 100
ng of MAZ, Sp1, and E2F-1 respectively also followed the RT-qPCR results. *p< 0.05
(versus control), as determined by Student’s t-test. All experiments were performed in a
minimum of triplicate.
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Figure 3-6. MAZ + Sp1 combination effect on pancreatic cancer cell lines. The pancreatic
cancer cells MiaPaCa-2, Panc-1, and AsPc-1 were transfected with MAZ (500 ng) + Sp1 (100
ng) plasmid; the mRNA expression of MAZ, Sp1, and kRAS were monitored. (A) Combination
of MAZ (500ng) and Sp1 (100ng) abrogated the decrease shown by MAZ and Sp1 individually
and lead to significant increase in fold mRNA kRAS expression in AsPc-1 and MiaPaCa-2 cell
lines. (B) The protein level by western blot showed the darkening of the band. *p< 0.05 (versus
control), as determined by Student’s t-test.
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3.4. Pancreatic cancer cell line specific TBB effects on kRAS
The protein CK2 is capable of phosphorylating MAZ and Sp1, and modulating their
affinity for binding DNA. Thus, we studied the effect of the CK2 inhibitor, TBB, on kRAS
promoter activity transcript and protein expression. The panel of pancreatic cancer cells were
treated with a dose-range of TBB to determine its IC50 in all the cell lines. The 48 hr IC50s for TBB
was determined to be 28 ± 0.6, 27 ± 0.1, and 13 ± 0.3 µM for MiaPaCa-2, Panc-1 and AsPc-1
respectively (Figure 3-7A). Cells were treated with their respective IC50s of TBB for 48 hr and the
mRNA levels of kRAS, MAZ and Sp1 were all monitored. The results were varied across cell
lines, with a significant decrease in kRAS measured in MiaPaCa-2 and Panc-1 cells, but
significantly increased kRAS noted in AsPc-1 cells (Figure 3-7B). Unexpectedly, significant
changes were also noted in MAZ transcription with a decrease in MiaPaCa-2 cells, and in Sp1
transcription with an increase in AsPc-1 cells. The mechanisms of such changes need to be
determined. Furthermore for the protein level also followed the RT-qPCR results with increase
kRAS protein levels in AsPc-1 and decrease in MiaPaCa-2 and Panc-1 cells (Figure 3-7C).
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Figure 3-7. TBB effect on kRAS expression in pancreatic cancer cell lines. (A) IC50 values of
pancreatic cancer cells treated with TBB after 48 hr. (B) MiaPaCa-2, Panc-1, and AsPc-1 were
treated with CK2 at their determined IC50s. There was an increase in fold change mRNA
expression of kRAS in AsPc-1, whereas TBB lead to significant decrease in MiaPaCa-2. Changes
in level of protein level on kRAS was also seen (C). *p< 0.05 (versus control), as determined by
Student t-test. All experiments were performed in a minimum of triplicate.
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3.5. MAZ, Sp1, and E2F-1 preferential binding to kRAS promoter regions and topologies
G4-forming regions are commonly associated with regulatory proteins such as Sp1, which
most often binds to dsDNA (Kumar et al. 2011), but stabilize some G4 structures (Raiber et al.
2012; Piekna-Przybylska et al. 2014). MAZ binds to and unfolds the hRAS promoter G4, leading
to the reactivation of gene expression (Cogoi et al. 2014). Recently in the same study where Sp1
bound H19 gene promoter G4 structure, E2F-1 also interacted with its G4 (Fukhura et al. 2017).
With such variations in structure recognition and effects, the binding of MAZ, Sp1, and E2F-1 to
varying topologies of the G4near, G4mid, and core kRAS promoter regions was examined using
EMSA. MAZ bound near ssDNA, all regions in dsDNA with more preference to near and core
region over mid region, and to both G4near and G4mid region of the kRAS promoter. Overall, MAZ
showed preferable binding to near regions of all three topologies (Figure 3-8A). Sp1 bound midssDNA, dsDNA, and G4-DNA respectively. Sp1 also showed binding to the near dsDNA (Figure
3-8B). Finally, E2F-1 ubiquitously bound all the regions and the topologies in the kRAS promoter
(Figure 3-8C).
By ECD, further investigation of the effect of MAZ, Sp1, and E2F-1 to the kRAS promoter G4s
stability was studied to find out any G4-interactive proteins. No significant effect on G4
stabilization was observed with MAZ or Sp1 (Figure 3-9). The E2F-1 pronouncedly destabilized
G4near by decreasing melting temperature by 7.68 °C (Figure 3-9). MAZ and E2F-1 modestly
stabilized G4mid by 2.56 and 2.11 oC respectively. On the other hand, Sp1 led to moderate
destabilization of G4mid by 2.57 oC (Table 3-1). ∆TM for MAZ and Sp1 compared to control to 2.56 oC and -2.57 oC change in mid G4 respectively (Table 3-1). No effect on the number of G4
isoforms present compared to control was observed with MAZ, Sp1, and E2F-1 can be denoted by
less than 1% change of the Hill slope as compared to the control.
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Figure 3-8. MAZ, Sp1, and E2F-1 binding to the kRAS promoter. EMSA was performed to
show binding of MAZ and Sp1 to different topologies (ss-, ds, and G4-DNA) and regions (core,
near, and mid). MAZ showed preferable binding to near (A), whereas Sp1 bind preferably to
mid all topologies (B). E2F-1 showed binding to all the regions and topologies (C).
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Figure 3-9. MAZ, Sp1, and E2F-1 effect on G4near and G4mid stability. By ECD, further
investigation of the effect of MAZ, Sp1, and E2F-1 binding to G4-DNA was studied. No
significant effect on G4 stabilization was observed with MAZ or Sp1. MAZ led to a slight right
shift in the G4near SVD graph, which is indicative of stabilization of G4 structure. E2F-1 leads
to a left shift in the G4near SVD graph, which is indicative of destabilization of G4 structure.
Not much effect on number of G4 isoforms were seen.
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Table 3-1. Effect of proteins on G4 stabilization. Denoted by ∆TM and number of
G4 isoforms shown by percent change of G4near and G4mid compare to control (KCl
+ 5% NE).
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3.6. Discussion
The region of the kRAS promoter between +50 and -510 has been previously identified as
being essential for its expression, but the TFs contributing to promoter region have not yet been
fully described. In this study, we mapped particular regions of the kRAS promoter for TF binding
sites, and further evaluated the binding and function of the TFs MAZ and Sp1 to the kRAS
promoter region, with a focus on three regions of interest – two G4-forming regions (near and mid)
and the core region from 0 to +50, relative to the TSS. MAZ and Sp1 individually act as
transcriptional silencers for kRAS expression as demonstrated in plasmid studies and pancreatic
cancer cell lines. Interestingly, the combination of MAZ and Sp1 leads to an increase in kRAS
promoter activity in both plasmids and pancreatic cancer cell lines. The role of CK2, a protein
kinase that can phosphorylate MAZ and Sp1 was also studied; changes in kRAS expression were
not consistent across cell lines as it decreased in MiaPaCa-2 and Panc-1 cells but increased in
AsPc-1 cells. It is worth noting that the TFs were not overexpressed in this experiment, and the
interplay between expression and phosphorylation is an area still under investigation. We also
demonstrated preferential affinity of the TFs for varying regions and DNA topologies within the
kRAS promoter.
To comprehensively understand the regulation of transcription initiation, one has to know
which TFs are controlling which gene. We used PROMO, which uses TRANSFAC database for
TF mapping studies. Our putative binding search showed that there are several consensus sites for
binding of several factors to the core promoter region: Sp1 (one), E2F-1 (four), WT1, GR-alpha,
p53, STAT4, and NF-AT1/2. Furthermore, near- and mid- G4-forming regions each contain a
number of putative transcriptional regulator binding sites as well, including two for MAZ (one at
the end of the near region and one in the midst of the mid-region), three for Sp1 (one in the near
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region and two within the mid-region), and several for p53, E2F-1, STAT4, WT1, NF-kB, and
more (Morgan et al. 2016).
We found out that MAZ binds different regions and topologies in kRAS promoter and this
interaction leads to decrease in kRAS promoter activity, transcripts and proteins level. Our finding
here contradicts the work done by Cogoi group, in which they showed MAZ binding to near G4
and duplex kRAS and this interaction leads to 3.5 fold increase in kRAS transcriptional activity in
Panc-1 cell lines (Cogoi et al. 2013). In murine kRAS promoter by luciferase assay, they proved
that MAZ as a kRAS transcriptional activator (Cogoi et al. 2010). We accomplished our studies
by a step-by-step approach, starting from the basic level to minimize the variables in our studies.
We first focused on the effect of MAZ in an isolated system of non-cancerous cell lines (HEK293), such as less noise or variation due to other factors as present in cancerous cells. Secondly,
we took in account broader panel of pancreatic cancer cell lines based on their kRAS addiction
pattern, and we also calculated the level of these proteins at basal levels in cell lines which are not
accounted for in previous studies. Further, we confirmed RT-qPCR transcriptional downregulation
by western blotting and found similar results showing reduce kRAS protein levels in these cell
lines at 500 ng of MAZ plasmids. Lastly, cell passage number plays a critical role in studies. The
studies performed by Xodo group doesn’t report the passage number of cells, this variability in
result might be due to older cell lines used. It has been shown previously with other cell lines that
expression levels of genes vary with different passage number (Chang et al. 1997; Driscoll et al.
2006; Hughes et al. 2007). On the other hand, to overcome this variability we performed our
studies with freshly acquired stock from ATCC.
Further work has been done to understand the transcriptional mystery behind kRAS.
Recently one such mechanism was studied. kRAS-E2F1-ILK-hnRNPA1 regulatory loop has been
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linked to oncogenic kRAS signaling promotion. This signaling involves destabilization of the G4
on the kRAS promoter by hnRNPA1, this activated kRAS that through E2F-1-mediated
transcriptional activation lead to the increase expression of ILK (Chu et al. 2016). It was further
shown that the destabilization by hnRNP A1 might be due to the unfolding of the kRAS G4
structure (Cogoi et al. 2017).
The TF MAZ is present in most, if not all, tissues (Bossone et al. 1992; Kennedy & Rutter
1992; Pyrc et al. 1992; Parks & Shenk 1996). MAZ was first identified as a GA-box–binding TF
in the c-MYC promoter, where it controls transcription initiation and termination (Bossone et al.
1992). MAZ has a complex functional role as it activates some genes (Her et al. 2003; Parks &
Shenk 1996; Song et al. 1998; Parke & Shenk 1997; Leroy et al. 2004), and repress others (Himeda
et al. 2008; Palumbo et al. 2008). We identified a silencer function for MAZ alone in relation to
the kRAS gene, although this finding disagrees with previous reports (Cogoi et al. 2010), as
described above. However, in combination of its partner Sp1, this silencing effect was abrogated.
Sp1 (5′-(G/T)GGGCGG(G/A)(G/A)(C/T)-3) recognition sites highly overlap with the
consensus binding sequences for MAZ (5’-GGGGGAGGGGGG-3’) (Kadonaga et al. 1986;
Ashfield et al. 1994), both sequences are often found in G4-forming regions. The Sp/XKLF
(Specificity protein/Krüppel-like factor) family first member identified was Sp1, which has three
contiguous Cys2His2 Zinc (Zn) finger DNA-binding domains, with Zn fingers 2 and 3 being
essential for DNA binding activity (Song et al. 2001). Sp1 forms complexes with many factors
associated with transcription (Li et al. 2004) and can act as transcriptional activator or repressor.
Recent CHIP-on-CHIP studies suggested the overlap of Sp1 (87%) binding sites with G4 forming
sequences. Which indicates Sp1 as an important G4 interactive protein. Since then several studies
have been published related to binding of Sp1 to several genes G4. In the c-KIT gene, Sp1 TF was
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shown to bind the G4 formed in the Sp1 binding sites (Raiber et al. 2012). Sp1 was also shown to
bind the HIV-1 promoter G4 and alter the promoter activity through this binding (PieknaPrzybylska et al. 2014). Recently it was shown that Sp1 also binds to the G4 in H19 gene and this
interaction suppresses the H19 transcription (Fukhura et al. 2017). Linking kRAS promoter to Sp1
has not been done before. Our studies demonstrated Sp1 acts as a transcriptional silencer for kRAS
expression though no effect or minimal effect on kRAS G4 stabilization.
Interestingly, the combination of MAZ and Sp1 expression mediated either no change or
an increase in kRAS expression in a cell line-specific manner. The binding of both proteins is also
regulated at the phosphorylation level by the kinase CK2. We indirectly studied the role of CK2
with its inhibitor TBB, and the findings were even more confounding, with a decrease in kRAS
noted in MiaPaCa-2 and Panc-1 cells, but an increase in AsPc-1 cells. The underlying mechanisms
of these changes remain to be determined. The role of CK2 in phosphorylation of MAZ and Sp1
their effects on another G4-containing promoter, c-MYC, was previously studied. In the 5'-end
promoter region of the c-MYC gene phosphorylation of MAZ by CK2 enhanced the binding
affinity of MAZ to the G4-forming pyrimidine-rich region of the nuclease-hypersensitive element
(NHE) (Tsutsui et al. 1999). On the other hand, CK2 phosphorylation of the C terminus of Sp1
resulted in a decrease in DNA binding activity; ultimately the differential binding of the proteins
led to transcriptional downregulation (Armstrong et al. 1997). In our studies treatment with CK2
inhibitor, TBB had cell specific effect on pancreatic cancer cell lines which might be related to
different basal levels of proteins, varied effects of binding of phosphorylated MAZ and Sp1, or
another unknown mechanism.
The E2F-1 was our selected third hit. The E2F TFs are key regulators of cell cycle
progression. They are known to control the transcription of gene products required for S phase.
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Whereas the recent microarray and CHIP studies shown wide variety of functions of E2F proteins
such as cell cycle transitions, differentiation, apoptosis, DNA repair, and checkpoint signaling
(Ishida et al., 2001; Ma et al., 2002; Muller et al., 2001; Polager et al., 2002; Ren et al., 2002). Ten
E2F family member genes, E2F1-E2F8 (He et al., 2000; Leone et al., 2000) exist. Among the E2F
family members, E2F-1 is unique in its ability to regulate a number of key genes that participate
in both cell cycle progression and apoptosis and behaves as both oncogene and a tumor suppressor
gene (Yamasaki et al., 1996). Thus, E2F-1 is a multi-functional damage responsive protein that is
involved in numerous aspects of the DNA damage response. Recently it was shown that E2F-1
binds to G4 structures in H19 gene (Fukhura et al. 2017). H19 is a gene found in humans which is
related to long noncoding RNA. Physiologically H19 is required for cell proliferation and as a
negative regulator (or limiting) of body weight (Gabory et al. 2009). H19 is highly expressed in
various cancers such as breast, colorectal, bladder, endometrial, esophageal, and lung (Kondo et
al. 1995; Elkin et al. 1995; Adriaenssens et al. 1998; Tanos et al. 2004; Ariel et al. 2000). H19
gene is responsible for tumor cell proliferation, colony formation, and tumor metastasis (Lottin et
al. 2002; Berteaux et al. 2005; Matouk et al. 2014).The interaction of H19 gene G4 to E2F-1 leads
to increase in endogenous H19 levels indicative of its role as transcriptional activator.
Overall, we have tried to understand the binding and functional role of MAZ, Sp1, and
E2F-1 in relation to the kRAS promoter. MAZ and Sp1 act as a transcriptional silencers for kRAS
and show binding to different DNA topologies, including the G4s. On the other hand E2F-1 acts
as transcriptional activator and binds to all DNA topologies and leads to significant destabilization
of G4near. Identification of the major transcriptional silencers and their effect on the dynamic
regulation of the kRAS promoter will provide an insight that is necessary for the development of
novel drug therapies, as this information can be a tool for future drug discovery related to kRAS
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transcriptional regulation. The strategies have been developed at downregulating kRAS by
blocking the formation of DNA–protein complexes at NHE by triplex-forming oligonucleotides
(Paramasivam et al. 2008 ) and use of decoy oligonucleotides against proteins binding to NHE of
hRAS promoter (Cogoi et al 2009; Cogoi et al. 2013). The understanding of significant TFs
regulating kRAS is necessary for the comprehension of a mechanism of action of exogenous (small
molecule) regulators of the kRAS expression and to utilize proteins as a target for pancreatic cancer
therapeutics in the future which has an abysmal 5-year survival rate (9%) and requires novel
therapeutic advancement to overcome the peril of pancreatic cancer.
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CHAPTER 4. GLOBAL BINDING OF TFs TO THE kRAS PROMOTER
4.1. Introduction
The largest group of human genes are enzymes, which account for 10% of all human genes;
TFs are the second largest group of proteins, comprising 6% (Venter et al. 2001). There are 1510
TFs (http://dbd.mrc-lmb.cam.ac.uk/DBD/index.cgi?Home), according to the current human TF
database, out of which less than 5% have been purified and characterized (Gadgil et al. 2001). In
the previous chapter, we did mapping studies on kRAS promoter which were based on weight
matrices and evolution. We found out that nearly 150-200 TFs bind to the kRAS promoter different
regions. Physical mapping and understanding the biological activity of these proteins is of utmost
importance in determining how genes are regulated. To understand these interactions, it is
necessary to understand the major proteins which are involved in transcriptional machinery.
Promoter regions contain several parts that play a vital role in transcriptional regulation.
The core promoter is regarded as the region of DNA, typically spanning from positions -50 to +50
relative to the transcription start site that is necessary to drive transcription of RNA polymerase II
(reviewed in Juven-Gershon et al. 2009). RNA polymerase II along with a number of basal TFs
are needed to drive transcription. Transcription Factor IIA (TFIIA), TFIIB, TFIID, TFIIE, TFIIF,
and TFIIH are the essential factors for RNA polymerase II-dependent transcription (Thomas &
Chiang 2006).The core promoter is comprised of TATA box, initiator element, Downstream
Promoter Element (DPE), Motif Ten Element (MTE), TFIIB Recognition Element (BRE), and
binding sites for RNA polymerase holoenzyme. TATA boxes, in eukaryotes, is frequently required
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for initiation of transcription. Approximately 30 nucleotides upstream of the transcription start site
(TSS) exist an A/T-rich sequence named as TATA box was the first core promoter element
discovered (Goldberg 1979). Aside from the TATA box, PIC assembly also requires several other
elements (Smale et al. 2003; Juven-Greshon et al. 2008; Butler et al. 2002). The first indication for
this came from the observation that the TBP-Taf complex TFIID gives an extended DNase I
footprint downstream from the transcription start site of certain promoters, suggesting that there
are elements besides the TATA box that can interact with the transcription machinery in a
sequence-specific manner (Sypes et al. 1994; Nakatani et al. 1990). Further investigation led to
the discovery of the Inr (Initiator), DPE (Downstream Promoter Element), DCE (Downstream
Core Element), and the MTE (Motif 10 element), all of which are conserved from drosophila to
humans and directly interact with various TFIID subunits (Burke et al. 1996; Burke et al. 1997;
Burke et al. 1998; Kadonaga 2002; Kutach et al. 2000; Lim et al. 2004). Additionally, the BRE
elements, located upstream and downstream of the TATA box (independently or together) are
recognized by the general transcription factor TFIIB (Deng et al. 2005; Deng et al. 2006; Deng et
al. 2007).
TATA box, it is utilized by a limited number of promoters (approximately 20%), and other
elements are equally important for PIC assembly (Basehoar et al. 2004; Yang et al. 2007).
Extensive mapping of transcription start sites and promoter elements in humans and mice revealed
that the majority of promoters of genes with constitutive levels of expression lack a well-defined
transcription start site or a TATA box (Yang et al. 2007; Carninci et al. 2006). The class of
promoters which initiate from a single well-defined nucleotide is much smaller and is enriched in
highly expressed tissue-specific genes regulated by a TATA box (Carninci et al. 2006). The
majority of genes fall into the TATA-less category and overlap extensively with the class of genes
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that are TFIID dependent and have steady levels of expression (Basehoar et al. 2004). kRAS is a
TATA-less promoter whose transcription regulation is not yet fully understood. These various
elements in the core promoter localize the binding of the RNA polymerase. After binding to the
DNA, the polymerase converts from the closed complex to the open complex to be available to
other co-regulators. To reveal the mechanism of gene expression of kRAS, the promoter regions
and binding sites for TFs must be characterized. For TATA-less promoters, the other core promoter
elements usually involved in transcriptional initiation include the binding of TFIID-associated
TBP-associated proteins (TAF) (Smale & Kadonaga 2003; Maston et al. 2006).
The activation or inhibition of transcription involves DNA response elements (REs) in
promoter regions, which are the binding sites for TFs. Other than common elements, GC-rich
promoters like kRAS consist of the GC-box element, to which TF's like Sp1 bind (Yamamoto &
Perucho 1988). Other than that there are developmentally specific (e.g., the B3 TF of Xenopus
oocytes), tissue specific (e.g., MyoD), and hormone specific TF's (e.g., the estrogen receptor) also
(Cooper 2000). A better understanding of transcriptional machinery requires promoter
characterization. Promoter characterization requires identification of each DNA element and their
protein binding profile. We showed in chapter 3 multiple putative binding sites for TFs in the
kRAS promoter regions. Herein we explore proteins shown to bind within the proximal promoter
region of the kRAS gene.
TFs can bind specifically to DNA cis-elements, modulating their binding in response to
external stimuli generally via protein or metabolite allosteric interactions. In making this
connection, they become the critical link in transferring information from the environment into
functional consequences. The prototypical prokaryotic TFs are mainly of the helix-turn-helix
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(HTH) fold family that selectively bind to the major groove of DNA using the second helix of the
TF (Cooper 2000).
TF functional investigation in gene regulation, biochemical, and structural studies involves
protein purification as a first step. Most complications in identification arise due to the TF
purification step, believed to be related to their large numbers and low abundance in human cells
(around <0.1%) (Woo et al. 2002), often leading to significant amounts of starting material
required for investigation.
Several methodologies have been employed to study the binding of TF to promoters. From
the early 1980’s, EMSAs have been used to quantify DNA binding activity and protein binding
(Matsuoka et al. 2003; Fried & Crothers 1981). The EMSA is a relatively simple procedure in
which an oligonucleotide of usually 20–25 bp, containing a response element (RE), and nuclear
extract or recombinant protein are incubated in binding buffer. When subjected to non-denaturing
polyacrylamide gel electrophoresis (PAGE), any TF-DNA complex migrates more slowly than the
free DNA, which can be visualized radioactively, fluorescently, or with ultraviolet light. The
combination of EMSA with proteomic techniques is frequently used for TF identification from
complex intracellular milieus. Two-dimensional gel electrophoresis (2-DE), which is a
combination of isoelectric focusing (IEF) and SDS-PAGE, is an example of TF-DNA binding
technique (Woo et al. 2002). Efficient renaturing of protein from a denaturing (SDS-PAGE) gel
for DNA binding activity analysis by EMSA is a prerequisite in this method, which can only detect
and characterize monomeric or homodimeric proteins. The second dimension of SDS-PAGE is
applied to the proteins bands and samples are identified by MS.
The binding affinity of TFs to REs is usually in the nM-pM range. In traditional affinity
chromatography, DNA is covalently attached to columns at μM or higher concentrations, which
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often leads to nonspecific protein binding and over-identification of proteins. Promoter trapping
was developed to overcome this shortcoming. In promoter trapping, nM concentrations of TFs are
incubated with duplex DNA (oligonucleotide or promoter) with a (GT)5 single-stranded tail,
enabling the formation of the specific TF-RE complex in solution. An (AC)5–sepharose column
traps the complex by annealing with the single-stranded (GT)5 of the oligonucleotide or promoter
(Gadgil & Jarrett 2002; Moxley & Jarrett 2005; Jiang et al. 2008). To further prevent the binding
of non-specific proteins, the trapping mixture is supplemented with specific binding modifiers,
such as heparin, T18, poly dI:dC and non-ionic detergent. Lastly, the trapped protein is eluted by
a high salt to disrupt TF-RE interactions, or by low salt with moderate temperatures. It must be
taken into consideration that the single stranded (GT)5 tail at 3′-end of double-stranded
oligonucleotide or promoter DNA leads to a nonspecific binding of hnRNP family members and
several other abundant nuclear proteins.
DNA affinity chromatography is the oldest technique used which takes into consideration
that TFs show higher affinity for binding to their consensus sites, as compared to for non-specific
DNA. In this technique, TFs are purified by exploiting their inherent capacity to bind to DNA by
utilizing chromatographic support (Vaquerizas et al. 2009). Currently, TF purification often
involves four or five different chromatographic steps that may include gel filtration, ion exchange,
and sequence-specific/nonspecific DNA affinity columns (Gadgil et al. 2001). Another
modification of DNA affinity chromatography is stable isotope labeling by/with amino acids in
cell culture (SILAC) (Mittler et al. 2009). It combines stable isotope labeling with an amino acid
in cell culture and one-step DNA affinity chromatography with quantitative proteomics to identify
specific TFs that bind to the methyl-CpG site in a promoter. It gives a better prediction and less
background by preventing identification of non-specific proteins (Mittler et al. 2009). These
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approaches are multiple-step, are not relevant to all research as they require homogenous tissue
culture, and are laborious.
In our experiments, we utilized a streptavidin-agarose pulldown approach to analyze
protein-DNA binding. This technique overcomes the shortcomings of EMSA, promoter trapping,
and DNA-affinity chromatography. It is an easy assay with minimal steps, not requiring special
columns or radiolabeled probes. The number of purification steps are fewer, as compared to DNAaffinity chromatography. The 5'-biotinylated double-stranded DNA probes and streptavidinagarose beads are incubated with nuclear extract proteins. The proteins are eluted from the pulled
down complex with 1M NaCl and analyzed by capillary liquid chromatography-tandem mass
spectrometry (LC-MS/MS) (Wu 2006).
TF purified by the above-mentioned procedures exist in very minute amounts (femtomole,
10−18) sample volumes. Only LC-MS/MS, or other sensitive proteomic approaches, can be used
for the characterization and identification of such small quantities of proteins. This process
requires several critical steps from sample preparation to analysis. The first step requires the
removal of contaminants such as plastics, salts, detergents, buffer components and any others that
may interfere with digestion. This is followed by pre-concentration, desalting, separation, and
ionization (Grosveld et al. 2005; Sebastian et al. 2002). The most critical step involves the
digestion of the TFs with sequence-specific exogenous protease(s); two types of digestions are
possible: in-gel and on-blot digestion.
To understand the function of TFs on kRAS expression, we first must identify the proteins
that bind to its promoter regions of interest. We hypothesized that several proteins bind to the
kRAS promoter different topologies and the binding of these proteins are expected to have a
different effect on kRAS transcription. Some might act as transcriptional activators, others as
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inhibitors, while still other may have no relevant biological activity. To investigate the hypothesis,
and overall tactic, a DNA pulldown-based purification approach, combined with proteomic
techniques for TF identification was used. Binding studies to different topologies of kRAS
(ssDNA, dsDNA, G4 DNA) of the regions of interest (core, G4near, and G4mid) within the kRAS
promoter were performed with nuclear extract to characterize protein interactions with the kRAS
core promoter region. Further, the biological role of these protein:DNA interactions to determine
the functional outcomes of these binding was determined.
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4.2. Binding and affinity of regulatory proteins and the kRAS promoter
To identify and characterize different regulatory proteins binding to the kRAS promoter
we utilized three approaches. The first approach utilized a DECipherment Of DNA Elements
(DECODE) database of proteins binding with the kRAS promoter. Several proteins were shown
to bind to the kRAS promoter. AP-2 and PPAR-γ were selected from the list as they show binding
in the core kRAS promoter region ± 50bp, which is involved in transcriptional initiation. The
whole genome rVISTA search portal (Zombon et al. 2005) showed four binding sites for AP2 and
one binding site for PPAR-γ (Figure 4-1).
The second approach utilized a Promoter Binding TF Profiling Plate Array kit (Signosis,
Santa Clara, CA). To characterize the TFs that bind to the kRAS core promoter region (-510/+50)
and potentially regulate the activation of the kRAS gene, 48 TFs were assessed for binding to the
kRAS promoter that was amplified by PCR from Panc-1 cell DNA, using a competitive promoterbinding TF profiling array. The kRAS promoter is a TATA-less promoter (Jordano & Perucho
1988); the protein TFIID binds to the TATA box only, so we were able to use it as a control to
normalize across duplicate data sets (Sawadogo & Sentenac 1990; Signosis protocol). A significant
change in transcriptional activity was assumed by 1.5-fold up- or down-regulation. Statistical
differences were determined by comparing the RLU of TFIID by use of a two-sided unpaired
Student‘s t-test (* p ≤ 0.05). Of the 48 total TFs, 14 showed an ability to compete for binding to
the kRAS promoter at significant levels (Figure 4-2B), including GATA (subtype undetermined),
Gr/PR, HIF, MYC-MAX, NF-1, NFAT, NF-E2, NF-κB, PPAR (subtype undetermined), Sp1,
Stat1, Stat3, Stat4, and Stat5.
For the third approach, the proteins that bind various regions and topologies of the kRAS
promoter were evaluated by us, in collaboration with the laboratory of Dr. Joshua Sharp, by DNA
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pulldown-LC/MS/MS (Wu 2006), which involves two major steps. First, biotinylated
oligonucleotides for different topologies (ss-, ds-, and G4-DNA) and regions (core, G4near, and
G4mid) were incubated with nuclear extract from Panc-1 and AsPc-1 respectively to form the DNAprotein complex. This complex then underwent several steps of washing and cleaning before
proteins were eluted with buffer containing 1M NaCl; excess detergent was removed using the
Pierce™ Detergent Removal Spin Column. A BCA assay was performed on the eluted proteins to
determine their concentrations, and proteins were identified and characterized by LC-MS/MS
(Figure 4-3). Data showed a significant number of proteins from Panc-1 and AsPc-1 nuclear
extract binding to different regions and topologies of the kRAS promoter (Figure 4-4). Proteins
of greatest interest were filtered on the basis of different # of spectra identified, their rank, and role
in transcription. # of spectra identified is a characteristic in MS identification and provides a
maximum probability of finding these proteins in samples. We had 33 proteins after the last step
(Table-2). We further selected 15 proteins including nucleophosmin, nucleolin, YBX-1, S100
A8/A9, hnRNPA1, TRIM28, PABPC-1, IGF2BP1, THO, 14-3-3, LYRIC, and BTF3 based on
their binding to different regions and topologies. Specifically, nucleolin, YBX-1, S100 A8/A9, and
14-3-3 bind to all regions and topologies. Addgene database was checked for the availability of
plasmids for future work. Out of them AP-2, PPAR-γ, YBX-1, and nucleolin were selected for
subsequent biological investigation.
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Figure 4-1. PPAR-γ & AP-2 binding sites. Qiagen Champion ChiP Transcription Factor
search portal showed and one binding site for PPAR-γ in a region of core kRAS promoter.
rVista online tool was used for identification of AP-2 binding sites to core kRAS core
promoter. It combines database searches with comparative sequence analysis, reducing
the number of false positive predictions by ~95% while maintaining a high sensitivity of
the search. Four binding sites for AP-2 in a region of core kRAS promoter were predicted.
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Figure 4-2. kRAS promoter-binding transcription factor profiling array.
Binding of various transcription factors present in the nuclear extract isolated
from Panc-1 cells to the kRAS promoter (-510 to +50) was assessed using the
Promoter-Binding Transcription Factor Profiling Array I. (A) The binding of each
transcription factor to kRAS was indicated by average reduction in
chemiluminescence of transcription factor-specific oligonucleotide probe specific
to each factor from duplicate samples. This 48-well plate shows the replicate of
lead compounds suggesting approximately 15 hits based on decrease in RLU (red
wells) indicative of high kRAS promoter-TF binding, and (blue wells) indicative
of no/low binding. (B) There were 7 TFs with significant decrease in RLU as
compare to TFIID.
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Figure 4-3. Schematic representation of DNA-pulldown method for identification of
kRAS binding TFs. (A) Pancreatic cancer cells nuclear extraction. Nuclear extract
incubation with kRAS oligos (ss-, ds-, and G4-DNA), followed by multiple washing steps,
and protein identification by LC-MS/MS.
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Figure 4-4. Number of proteins determined by LC-MS/MS. AsPc1 and Panc-1 nuclear
extract, number of proteins identified for each region (core, near, mid) and topology (ss-, ds, and, G4-DNA n=1).
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Table 4-1. Proteins identified by LC-MS/MS. The table represent the name of protein its protein
identification number, number of spectra identified, and ranking in parenthesis which was based on
best score assigned by the software.
Protein

PDB

Ss Near

Ss Mid

P19338

Ss
Core
17 (67)

Ds Near

Ds Mid

15 (31)

Ds
Core
18 (34)

Nucleolin

36 (39)

G4
Core
17 (50)

G4
Near
9 (69)

G4
Mid
7 (69)

9 (70)

YBX-1

P67809

45 (26)

12 (34)

YBX-3

P16989

7 (71)

20 (35)

6 (50)

16 (16)

0

0

0

41 (24)

52 (19)

27 (10)

22 (16)

19 (16)

22 (30)

46 (27)

17 (32)

8 (41)

8 (51)

Nucleopho
smin
S100 A8

P06748

21 (74)

15 (127)

6 (136)

10 (96)

7 (163)

12(205)

0

0

4 (116)

P05109

8 (108)

7 (117)

S100 A9

P06702

7 (62)

10 (56)

6 (227)

3(264)

10 (68)

6 (101)

10 (26)

4 (129)

hnRNP R

O43390

0

3 (146)

3 (159)

4 (101)

0

0

10 (64)

9 (60)

6 (61)

0

0

0

7 (239)

0

0

0

hnRNP F

P52597

0

0

0

0

8 (87)

20 (52)

8 (99)

7 (113)

hnRNP A1

P09651

12
(145)
9 (167)

0

0

0

0

3 (328)

13
(102)
9 (72)

0

0

hnRNP U

Q00839

0

9 (220)

5 (56)

6 (107)

6 (176)

13 (59)

0

0

0

hnRNP M

P52272

0

0

2 (158)

0

7 (206)

0

3 (116)

4 (81)

6 (79)

hnRNP L

O14979

4 (128)

0

0

0

7 (194)

10 (89)

0

0

0

TRIM28

Q13263

4 (161)

0

0

4 (129)

14 (49)

10 (85)

4 (97)

8 (73)

11 (29)

PABPC1

P11940

11 (79)

6 (61)
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4.3. Transcriptional activator/silencing effect of proteins on kRAS promoter
As described in previous chapters, we first sought to examine the effects of the identified
proteins effect on kRAS transcription and to further define the DNA regions and structures to
which the proteins bind. A luciferase assay was performed in HEK-293 cells transfected with a
luciferase plasmid driven by the kRAS promoter Full Length (FL) in the presence of increasing
amounts of the AP-2, PPAR-γ, YBX-1, and nucleolin the expression plasmids; a promoter-less
vector (EV) was included as a control. A correlative relationship was found between the proteins
AP-2, PPAR-γ, and nucleolin with kRAS transcription as inferred from luciferase expression. As
compared to EV, AP-2 increased promoter activity by 30% (1.300 ± 0.104), over 170% (2.767 ±
0.209), and by 300% (4.064 ± 0.295), at 250, 500, and 1000 ng of expression plasmid, respectively
(Figure 4-5A). PPAR-γ showed an increase by 100% (2.094 ± 0.143), and almost 180% (2.782 ±
0.075), at 500 and 1000 ng of expression plasmid, respectively (Figure 4-5B). Nucleolin increased
kRAS promoter activity by over 30% (1.355 ± 0.155), and 90% (1.920 ± 0.068), at 500 and 1000
ng, respectively (Figure 4-5C). Our fourth protein of interest, YBX-1, showed an inverse
relationship with kRAS expression, with significant decreases in the promoter activity by almost
70% (0.336 ± 0.013), 80% (0.200 ± 0.015), and by 83% (0.170 ± 0.015), at 250, 500, and 1000 ng
of expression plasmid, respectively (Figure 4-5D).
We extended these studies to examine the effect of AP-2, PPAR-γ, YBX-1, and nucleolin
on kRAS transcription in more complex milieus with pancreatic cancer cell lines. MiaPaCa-2,
Panc-1, and AsPc-1 were transfected with increasing protein expression plasmids and the effects
on endogenous kRAS expression was monitored and normalized to the housekeeping gene,
GAPDH. In these more complicated environments, with variations in basal levels of the proteins
(Figure 4-6) studied, as well as in overall genetics, the findings are not as easy to interpret. In the
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cells, AP-2 had no effect on kRAS transcription in the MiaPaCa-2 and AsPc-1 cells. In contrast to
the plasmid findings, kRAS expression decreased in Panc-1 cells (Figure 4-7A). The PPARγ:kRAS promoter interaction was more consistent with the plasmid findings: while there was no
change in kRAS expression in MiaPaCa-2 cells, it significantly increased in both Panc-1 and AsPc1 cells by 2.5 fold and 1 fold respectively (Figure 4-7B). The nucleolin:kRAS promoter interaction
was confounding with an array of responses. At lower increased of nucleolin (1.5 – 4.5-fold),
kRAS expression increased 0.50 in MiaPaCa-2 cells, did not change in Panc-1 cells, and
significantly decreased in AsPc-1 cells (Figure 4-7C). Transfections with more plasmid and
subsequent higher expression of nucleolin demonstrated a complex interaction with a significant
decrease in kRAS expression in MiaPaCa-2 cells, a significant increase in Panc-1 cells, and no
change in AsPc-1 cells (Figure 4-7D). More work is ongoing to decipher the precise interaction
of this known G4-interactive protein with the kRAS promoter. YBX-1, seen to significantly
decrease kRAS promoter activity in plasmids, mediated a significant increase in kRAS
transcription in AsPc1 cells lines (Figure 4-7E).
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Figure 4-5. AP-2, PPAR-γ, nucleolin, and YBX-1 effect on kRAS promoter activity. A
luciferase assay was performed in HEK-293 cells transfected with a luciferase plasmid driven by
the kRAS promoter in the presence of increasing AP-2, PPAR-γ, nucleolin, and YBX-1
expression plasmid. Promoterless (EV) was included as a control. Increased AP-2, PPAR-γ, and
nucleolin expression led to decreased kRAS promoter activity as measured by fold change in
RLU, normalized to the EV effect. (A-C). YBX-1 led to a significant decrease in kRAS promoter
activity (D). *p< 0.05 (versus control), as determined by one-way ANOVA with Tukey post-hoc
testing. All experiments were performed in a minimum of triplicate.
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Figure 4-6. Basal levels of AP-2, PPAR-γ, nucleolin, YBX-1, and kRAS in pancreatic
cancer cell lines. At Basal level (0 ng) the proteins expression are normalized to MiaPaca-2
cells. AsPc-1 showed highest level of kRAS and AP-2. On the other hand Panc-1 showed the
highest level of PPAR-γ, nucleolin, and YBX-1.
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Figure 4-7. AP-2, PPAR-γ, nucleolin, and YBX-1 effect on pancreatic cancer
cells. The pancreatic cancer cells MiaPaCa-2, Panc-1, and AsPc-1 were
transfected with increasing AP-2, PPAR-γ, nucleolin, and YBX-1 plasmid; the
mRNA expression of proteins and kRAS were monitored. (A) The AP-2:kRAS
interaction led to significant decrease in Panc-1. (B) The PPAR:kRAS, promoter
interaction led to significant increase in Panc-1 and AsPc-1 cell lines at 500 ng.
(C) The effect of nucleolin:kRAS, promoter interaction varied on on the amount
of plasmid transfected. (D) Finally, the effect of YBX-1:kRAS, promoter
interaction showed a significant increase in kRAS mRNA expression in AsPc-1
cell lines only. *p< 0.05 (versus control), as determined by one-way ANOVA with
Tukey post-hoc testing. All experiments were performed in a minimum of
triplicate.
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4.4. The G4 kRAS (near and mid) stability profile of proteins
The binding affinity of AP-2, PPAR-γ, YBX-1, and nucleolin to various regions and
topologies of the kRAS promoter was examined using EMSA. As detailed previously, biotinlabeled oligonucleotides (4 μM) of the near- and mid -G4 forming regions were incubated at 95
°C for 10 min followed by slow cooling to form G4s. The dsDNA were formed in the thermal
cycler by incubating with the complementary strand at 95 oC for 5 minutes followed by 70 cycles
of 95 oC (-1 oC/ cycle). The 1X agarose gel was run to confirm the formation of ssDNA and dsDNA
(Data not shown). The ss-, ds-, and G4-DNAs were incubated with AP-2, PPAR-γ, YBX-1, and
nucleolin nuclear extract (0-20 µg/µl) for 30 min at room temperature. We also did a dose-response
to see the effect of incubation of different amount of nuclear extract on DNA binding (data not
shown). AP-2 showed favorable binding to ss, ds-core and to G4-near regions (Figure 4-8A).
PPAR-γ bound only to the ds mid region (Figure 4-8B). Nucleolin showed binding to all the
regions and topologies (Figure 4-8C). YBX-1 showed binding to various regions and topologies
as well. Shifts were notable with the ss and G4 forms of the mid-region, and with all regions in
dsDNA form, although most markedly with the near region (Figure 4-8D).
Further investigation of these proteins binding to G4-DNA was done by ECD. Unlabeled
oligonucleotides (5 μM) of the kRAS G4 sequences of the near, and mid G4-forming sequence
after the formation of G4 with heating and cooling at 95 oC for 10 minutes with 100 mM KCl were
incubated with either protein elution buffer, or the nuclear extract, with (to see effect on
stabilization profile of a G4) and without (as control for comparison). No significant effect on
G4mid stabilization was observed with AP-2, PPAR-γ, and YBX-1 (Figure 4-9A). The nucleolin
pronouncedly destabilized G4mid (Figure 4-9B) by decreasing the melting temperature by 15 °C
and showed no significant effect on G4near (Table 4-3). As nucleolin has been previously shown
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to interact with and stabilize RNA and the MYC G4, this was an unexpected finding, although it
is in agreement with an increase in transcription noted with plasmids and to a varying degree in
cell lines, as described above.
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Figure 4-8. AP-2, PPAR-γ, nucleolin, and YBX-1 binding to the kRAS promoter. EMSA was
performed to show binding of AP-2, PPAR-γ, nucleolin, and YBX-1 to different topologies (ss-,
ds, and G4-DNA) and regions (core, near, and mid). (A) AP-2 showed favorable binding to all
near and mid regions. (B) PPAR bind preferably to ds mid region. (C) Nucleolin showed binding
to all the regions and topologies. (D) Finally, YBX-1, like nucleolin showed binding to all with
more preference to ds-DNA.
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Figure 4-9. Effect on kRAS G4 stability profile. By ECD, further investigation of the effect of
AP-2, PPAR-γ, nucleolin, and YBX-1 binding to G4-DNA was studied. No significant effect on
G4 stabilization was observed with AP-2, PPAR-γ, and YBX-1. The nucleolin pronouncedly
destabilized G4mid by decreasing melting temperature by 15 °C and showed no significant effect
on G4near.
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Table 4-2. Effect of proteins on G4 stabilization as denoted by ∆TM and number of G4
isoforms shown by percent change of G4near and G4mid compare to control (KCl + 5% NE).
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4.5. Discussion
Herein, we utilized empirical methods to identify proteins of interest binding to the kRAS
promoter, including a database of ChIP data, binding studies to the whole promoter, and
identification of proteins binding to distinct regions of interest. This was done to generate a more
global picture of TF binding to the kRAS promoter that extends from 300-500 bases downstream
from the transcriptional start site (TSS) to 50 bases upstream and contains two distinct putative
G4-forming regions. From these studies, there were several hit proteins, including many whose
function and involvement is yet to be determined, such as GATA, Gr/PR, HIF, MYC-MAX, NF1, NFAT, NF-E2, NF-κB, PPAR, Sp1, Stat1, Stat3, Stat4, and Stat5. From the cumulative
approaches, we focused on four proteins: AP2, PPAR-γ, YBX-1, and nucleolin.
AP2 had four binding sites at the core promoter region from 0 to +50 bp according to the
Qiagen Champion ChiP Transcription Factor detection. It also was identified as a hit protein in our
TF array kit. Homologous proteins of 52 kDa form the AP2 family of proteins, which include
Tfap2a, Tfap2b, Tfap2c, Tfap2d, and Tfap2e (Cheng et al. 2002; Feng & Williams 2003; HilgerEversheim et al. 2000; Tummala et al. 2003; Williams et al. 1988; Zhao et al. 2001). In the nucleus,
AP2 mediates both activating and repressing stimuli to their targets by binding to the GC-rich
consensus sequences, fostering homo- or hetero-dimerization of the AP2 proteins via their
dimerization motifs (Bosher et al. 1996; Hilger-Eversheim et al. 2000; Williams & Tjian 1991a;
Williams & Tjian 1991b).
AP2 proteins are involved in several targets associated with a different level of cancer
development, in a cell-specific manner. Reduced tfap2a is observed in tumor cells of malignant
melanoma, during metastasis, inhibition of tumor growth by increasing cell death is observed by
forced expression of Tfap2a in these cells (Bar-Eli 2001; Huang et al. 1998). On the other hand,
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overexpression of Tfap2c promotes cell proliferation and tumor growth in a murine breast cancer
model (Jager et al. 2005). AP2 proteins because of their structural conservation share similar
transactivating properties (Bosher et al. 1996; McPherson & Weigel 1999). For example, both
Tfap2a and Tfap2c are capable of inducing p21WAF1 expression and inhibiting proliferation (Li
et al. 2006; Zeng et al. 1997). The expression of human epidermal growth factor receptor-2 (HER2)
is activated by Tfap2a and Tfap2c, as well as Tfap2b, in breast cancer cell lines (Bosher et al.
1996; Bosher et al. 1995; Hollywood & Hurst, 1993; Li et al. 2002). Cell adhesion molecule
MCAM/MUC18, protease-activated receptor 1 (PAR-1), estrogen receptor alpha (ER-α), and the
tyrosine-kinase c-Kit are some other targets of AP2 (Bar-Eli 2001; Huang et al., 1998; Jean et al.,
1998; McPherson et al., 1997; Tellez et al., 2003). The complexity of AP-2 proteins’ regulatory
control increases manifold with its transcriptional co-factors, such as Ying Yang 1 (YY1), p53,
Sp1, Myc, Pax6, retinoblastoma protein (pRB), cAMP response element binding protein (CREB),
CREB-binding protein (CBP)/p300, and CBP/p300-interacting transactivator with ED-rich tail 2
and 4 (CITED 2 and 4) (Batsche et al. 1998; Braganca et al. 2003; Braganca et al. 2002; McPherson
et al. 2002; Pena et al. 1999; Sivak et al. 2004; Wu & Lee 1998; Wu & Lee 2001).
Moreover, several lines of evidence suggested that AP2α might behave as a tumorsuppressor gene (TSG) in several tissues. For example, loss of AP2α expression was reported in
metastatic melanoma cells (Tellez et al. 2003), in prostate (Ruiz et al. 2001) and colon cancer cells
(Schwartz et al. 2007). In breast cancer cells, contrasting results were reported in the literature.
Earlier studies suggested that AP2 proteins promote the malignant potential of breast cancer cells
by transactivating the promoters of ErbB-2 and ErbB-3 (Bosher et al. 1996). However, recent data
using shRNA to knockdown AP2α expression in breast cancer cell lines showed that AP2α inhibits
tumor growth both in vitro and in vivo (Orso et al. 2008). Colon and breast cancer cells sensitivity
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towards chemotherapeutic drugs is controlled by AP2α (Wajapeyee et al. 2005). Despite its
potential interest, the roles of AP-2α in pancreatic cancer is not yet studied extensively
(Vernimmen et al. 2003). In human pancreas, AP2α was expressed by almost 66% of non-tumoral
ductal cells and endocrine cells, whereas its expression was decreased to only 5.5% of pancreatic
ductal adenocarcinoma (PDAC) (Fauquette et al. 2007). Moreover, AP2α expression was mutually
exclusive with that of the human epithelial mucin, MUC4, which is a specific marker of PDAC
and is expressed in 83% of the patients (Jonckheere 2009). The relationship of AP2 and kRAS
transcription has not been explored before. Herein, we showed the binding of AP2 to the kRAS
promoter, and that binding leads to increase kRAS promoter activity in HEK-293 cells and
differential effects on pancreatic cancer cells, which might have a role in pancreatic cancer which
has not been looked into before.
Peroxisome proliferator-activated receptors (PPARs), of which our second hit, PPAR-γ, is
a member, are a group of ligand-activated TFs and nuclear hormone receptor superfamily
members. There are three separate genes that give rise to the different isoforms of PPAR, termed
PPAR-α, β/δ, γ. Due to differential splicing and alternate promoter usage, there are three isoforms
of gamma - γ1, γ2, γ3 (Fajas et al. 1998; Desvergne & Wahli 1999; Roberts-Thomson 2000). Each
of the PPAR isoforms has a different tissue distribution, function, and to some extent, different
ligand specificity. PPARα is expressed primarily in the liver, heart, kidney, skeletal muscle and
brown adipose tissue. PPARβ/δ expression is ubiquitous, while PPAR-γ is primarily found in white
and brown adipose tissue, large intestine and spleen (Desvergne & Wahli, 1999). In normal
physiology, PPAR-γ is involved in adipogenesis, insulin resistance, regulation of lipid
homeostasis, and in the development of various organs. In addition to these metabolic processes,
PPAR-γ is overexpressed in several types of human cancers, including breast, colon, bladder, and
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prostate cancer (Sikka et al. 2012). The mechanism of binding of PPARs is a multistep process.
Activated PPARs first form a heterodimer with the retinoid X receptor and this complex binds to
peroxisome proliferator response element (PPRE), which is a specific sequence in the promoter
region of target genes (Isseman et al. 1993; Roberts-Thomson 2000). Its activation leads to
inhibition of cell growth and promotion of differentiation in many epithelial derived cancer cell
lines (Sarraf et al. 1995; Tontonoz et al. 1997; Elstner et al. 1998; Mueller et al. 1998; Kubota et
al. 1998; Mueller et al. 2000; Chang & Szabo 2000).
Activated PPAR-γ decreases pancreatic cancer cell growth and their migration and invasive
capacity (Motomura et al. 2000; Toyota et al. 2002; Tsujie et al. 2003; Motomura et al. 2004;
Adrian et al. 2008; Kumei et al. 2009). Using a pancreatic carcinoma xenograft model of nude
mice, PPAR-γ activation inhibited pancreatic cancer growth and suppressed tumor angiogenesis
(Dong et al. 2009). However, like in other types of cancers, the role of PPAR-γ in pancreatic cancer
remains controversial (Eibl 2008). In contrast to the above studies, PPAR-γ expression in
pancreatic cancer was correlated with shorter patient survival suggesting a role for PPAR-γ in
tumor progression (Kristiansen et al. 2006). Due to contradictory results in mice versus human,
further investigations are still needed to clarify the role of PPAR- γ in pancreatic cancer. So, having
a profound effect on several types of cancers and it being identified as a hit in our studies resulted
in moving with PPAR-γ as the second hit against kRAS regulation.
In 1970's Y-box binding proteins were first described and characterized in animals
including duck, rabbit, and amphibians (Morel et al. 1973; Morel et al. 1971; van Venrooij et al.
1977). Y-box-1 protein was sequenced in 1988 and was found to interact with the Y-box motif in
the promoter of the major histocompatibility complex class II genes (Didier et al. 1988). It binds
to an inverted CCAAT box (5′-CTGATTG-GC/TC/TAA-3′) in the Y box of the promoter. There
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are three families of YB proteins namely YBX-1, -2, and -3 respectively. In embryonic tissues,
there is a high-level YBX-1 expression in heart, muscle, lung, adrenal gland and brain, and low
amounts in thymus, kidney, bone marrow and spleen (Spitkovsky et al. 1992). YBX-1 has been
demonstrated to be vital for normal embryonic development, particularly late embryonic
development in mice (Lu et al. 2005). Mice that were YBX-1 (-/-) developed growth retardation
after 13.5 days, exencephaly, craniofacial defects and progressive mortality. In prostate, breast,
ovarian, brain, colorectal cancer YBX-1 overexpression is detected as an adverse prognostic factor.
It has been implicated in several other cancers, including gastric cancer (Wu et al. 2012), bladder
cancer (Shiota et al. 2011), oesophageal cancer (Li et al. 2011), osteosarcoma (Oda et al. 2003;
Oda et al. 1998), lung cancer (Gessner et al. 2004; Shibahara et al. 2001), melanoma (Schittek et
al. 2007) and liver cancer (Yasen et al. 2005). YBX-1 binds single-stranded DNA with high affinity
(Izumi et al. 2001), although in our findings we demonstrated binding to multiple DNA topologies,
including dsDNA.
The increased YBX-1 expression is observed in PDAC. Nuclear YBX-1 expression is
associated with dedifferentiation, lymphatic/venous invasion, and unfavorable prognosis. On the
other hand YBX-1 knockdown leads to inhibition of cell proliferation via cell cycle arrest by Sphase kinase-associated protein 2 downregulation, and decrease in the invasion due to
downregulated membranous-type 2 MMP expression in PDAC cells. YBX-1 targeting antisense
oligonucleotide significantly inhibited the growth of subcutaneous tumors. In conclusion, YBX-1
was shown to be involved in aggressive natures of PDAC and is a promising therapeutic target
(Shinkai et al. 2016). For these reasons and due to its availability, we selected it as our third hit for
biological evaluation. The results obtained were not conclusive and require further investigation
to determine its role in pancreatic cancer.
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The fourth protein of interest which was chosen for further study was nucleolin. In 1973,
nucleolin was discovered in rat liver cells (Pinard 1973). It is present in the nucleolus of plants,
yeast, and mammals (Genisty et al. 1999; Yang et al. 2008). Human nucleolin consists of 707
amino acids with a calculated mass of 77 kDa (Srivastava et al. 1989). Nucleolin helps to regulate
RNA polymerase II transcription of genes by interacting with several TFs (Tajrishi et al. 2011;
Masumi et al. 2006; Huddleson 2006). Nucleolin also functions in chromatin remodeling (Hans
et al. 2006; Mongeland & Bouvet 2007), transcription (Yang et al. 1994; Grinstein et al. 2002;
Grinstein et al. 2007; Brys & Maizels 1994; Dampsey et al. 1990), apoptosis (He et al. 1998), and
G4 binding (Dampsey et al. 1990; Hanakahi et al. 1999; Bates et al. 1999). Nucleolin binds and
stabilizes the c-MYC gene G4 formed in the promoter region. This lead to the downregulation of
c-MYC transcription, acting as a repressor of c-MYC (Gonzalez et al. 2009; Gonzalez et al. 2010).
It binds the G4 structure in the promoter region of human vascular endothelial growth factor
(VEGF) (Sun et al. 2011) and in ribosomal RNA (Hanakahi et al. 1999).
Nucleolin inhibition reduces tumor growth in renal cell cancer and breast cancer (Bates et
al. 2009; Pichiorri et al. 2013). In the recent study, a low level of nucleolin was linked with
significantly increased survival in PDAC patients. The growth of primary tumors and liver
metastasis in an orthotopic mouse model of PDAC (mPDAC) was impaired by the nucleolin
antagonist N6L. In pancreatic cancer, targeting nucleolin by N6L is hailed as a new anti-cancer
therapeutic strategy as it leads to blocking tumor progression, normalizing tumor vasculature,
improving the delivery and efficacy of chemotherapeutic drugs (Gilles et al. 2016). One study
described interactions between nucleolin and kRAS in the nucleolus (Birchenall-Roberts et al.
2006). Endogenous nucleolin t C-terminal to interacts simultaneously in vivo with endogenous
RAS and ErbB1 (EGFR) in cancer cells (Farin et al. 2011). Most importantly, these three
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oncogenes synergistically facilitate anchorage-independent cell growth in vitro and tumor growth
in vivo (Farin et al. 2011). In our studies, nucleolin binds to the kRAS core and mid, but not much
to near and only a little in the ds form and led to an increase in transcription. Previous studies
showed that overexpression of nucleolin is associated with tumor growth. On the other hand,
nucleolin was also showed to destabilize the kRAS G4 structure, which might contribute to its role
in activating transcription. Further studies on folding profile and its role in cancer progression is
warranted.
Through our studies, we identified four potential transcriptional regulators of kRAS. AP2,
YBX-1, and PPAR-γ alter the kRAS transcription in a non-G4 interactive manner. In contrast, and
in a similar manner to the MYC and VEGF structures, nucleolin also binds to the G4mid kRAS
promoter. Interestingly our studies demonstrated a destabilization effect, whereas nucleolin has
been seen to stabilize the MYC structure; nucleolin apparently mediated increase in kRAS
expression overall, by destabilization of the kRAS G4mid structure. The laboratory will continue to
investigate the relevance of the interaction of all TFs and kRAS promoter to understand the
mechanism behind the regulation. The mechanism of regulation for the G4-binding proteins, such
as nucleolin, might be through altering the stability profile of the G4 present in the kRAS promoter.
Understanding the transcription machinery of kRAS is important to understand the biological role
of these regulatory proteins behind tumor formation, maintenance, and metastasis. This
information will be useful in the future for the development of novel cancer therapies by
deliberately and specifically altering their binding to the kRAS promoter or by utilizing them to
alter the G4 stability profile with the final aim of altering the expression of kRAS.
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CHAPTER 5. G4-INTERACTIVE COMPOUNDS AS NOVEL SMALL MOLECULE
TRANSCRIPTION INHIBITORS OF PANCREATIC CANCER
5.1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive form of pancreatic cancer that
accounts for 90% of total pancreatic cancer cases (Ryan et al. 2014). The treatment of PDAC has
not improved in 30 years (Wolfgang et al. 2013) as the 5-year survival rate is dismal at 7% (SEER
Cancer Statistics, 2015. PDAC progression also involves the loss or mutation of several other
tumor suppressor genes (Vincent el al. 2011) such as cyclin‐dependent kinase inhibitor 2A
(CDKN2A) (Schutte et al. 1997), TP53, and the SMAD4 (Malkoski et al. 2012). Out of these,
kRAS is the prime player in pancreatic cancer, and was identified as a key target for cancer
research by a kRAS pancreatic cancer working group (NCI) in the establishment of the RAS
Initiative Center in Frederick, MD (Abbruzzese 2013).
The RAS family of small GTPases includes three genes: HRAS, NRAS, and kRAS which
encode: HRAS, NRAS, kRAS4A, and kRAS4B proteins. RAS mutations are observed in residues
12, 13 and 61, and effect the GTP hydrolysis activity (Vigil et al. 2010). RAS In bladder, ovary,
thyroid, lung, colon and pancreatic cancer kRAS is mutated. kRAS codon 12 mutations occur most
frequently in pancreatic cancer (Prior & Lewis 2010). kRAS protein is critical in cancer signaling
due to their active role in cell differentiation, proliferation, migration, and apoptosis (Cox et al.
2010). After activation from upstream signals and mutations, RAS‐GTP acts as a molecular switch
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and activates different downstream effectors which regulate a myriad of cytoplasmic signaling
networks.
After more than three decades of intensive effort, no anti-RAS therapy has been clinically
employed (Stephen et al. 2014; Bryant et al. 2014; Cox et al. 2014). Six promising paths have been
looked at to find an effective treatment for kRAS-mutant cancers, including kRAS direct
inhibitors, membrane association inhibitors, synthetic lethal interactors, kRAS downstream
effector signaling pathways inhibitors of kRAS, kRAS metabolic process regulators, and
harnessing the immune response.
Direct targeting of kRAS has primarily focused on inhibiting protein-protein interactions
necessary for activation. Targets of this approach include the RAS-GEF1 recognition pocket (Sun
et al. 2012; Maurer et al. 2012) and downstream effector pathway interactions (Shima et al. 2013).
Notably, an RNA interference (RNAi) strategy was used to suppress kRAS expression and has
shown positive pre-clinical results in kRAS mutant-driven mouse models of lung and colorectal
cancer (Yuan et al. 2014; Xue et al. 2014), but due to delivery issues and poor pharmacokinetic
profile, it has not reached clinical phase. This last strategy is most applicable to our approach and
its limitations are ones that G4-targeting can putatively overcome.
Interruption of kRAS plasma membrane localization by inhibiting the farnesyltransferase
enzyme has also been pursued therapeutically (Queneau et al. 2001; Rowinsky et al. 1999; End
1999). Clinical trials of Farnesyl Transferase Inhibitors (FTIs) to treat PDAC were unsuccessful
(Basso et al. 2006; Berndt et al. 2011), mainly due to an alternative localization pathway with the
geranylgeranyl transferase enzyme, which overcomes the actions of FTI treatment. A third
approach has been exploiting synthetic lethal interactions. Synthetic lethality interactors are the
combination of genes whose loss of function in the presence of mutant kRAS would lead to cell
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death. These include CDK1, TPX2, TFs such as GATA2, serine/threonine protein kinase 33
(STK33) and TBK1 (Sarthy et al. 2007; Morgan-Lappe et al. 2007; Stecket et al. 2012; Kumar et
al. 2012; Barbie et al. 2009; Muvaffak et al. 2014). Inhibition of these has not shown any promise
in inhibiting pancreatic cancer progression.
The most encouraging of all approaches has been targeting the downstream effector
pathways. Six of the eleven RAS effector families identified to date, have validated roles in
contributing to RAS-dependent cancer initiation and maintenance (Cox et al. 2015; Baines et al.
2011). MEK1/2 and ERK1/2 interaction with BRAF serine/threonine kinases are a major
downstream effector pathways of kRAS-mediated oncogenesis. Rigosertib (2‐[(2‐Methoxy‐5‐
{[(E)‐2‐(2,4,6‐trimethoxyphenyl)ethenesulfonyl]methyl}phenyl)amino]acetic acid), a benzylstyryl sulfone, acts as RAS-mimetic and interacts with the RAS binding domains (RBDs) of RAF
kinases. This binding alters their ability to bind to RAS, disrupts RAF activation, and ultimately
leads to inhibition of the RAS-RAF-MEK pathway. Rigosertib also binds to the RBDs of Ral-GDS
and PI3Ks (Ostrem & Shokat 2016; Athuluri-Divakar et al. 2016; Cox et al. 2015).
Another important parallel pathway is that of PI3K-AKT-mTOR. There are four main
pharmacologic approaches for inhibition of PI3K signaling: PI3K inhibitors, AKT inhibitors, and
mTOR inhibitors, and dual PI3K-mTOR inhibitors (Cox et al. 2014; Fruman & Rommel 2014).
Previously, in a lung cancer murine model harboring upregulated kRAS, PI3K inhibition led to
partial regression of tumor growth (Ebi et al. 2011; Castellano et al. 2013; Gupta et al. 2007). On
the other hand, evidence suggests that this pathway is not a significant effector for RAS signaling
alone. However, combination of PI3K pathway inhibitors with RAF-MEK-ERK cascade inhibitors
leads to potent synergistic activity (Engelman et al. 2008). Specifically, treatment with MEK
(GDC-0973) or PI3K inhibitors (GDC-0941) alone in mice PDAC model showed slight tumor
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growth inhibition with no significant effect on survival. On the other hand, the combination of the
two treatments resulted in a survival advantages (Junttila et al. 2015). Many of these anticancer
drugs have not passed clinical trials due to their lack of specificity and selectivity for mutant kRAS,
as well as, causing the activation of parallel pathways resulting in tumor growth and disease
progression (Adjei 2001). Another approach includes kRAS-regulated metabolic targets related to
glycolysis and glutamine metabolism (Bryant et al. 2014). Cancer cells display altered levels of
glycolysis along with increased dependency on glutamine. Strategies include inhibition of
enzymes related to these pathways such as glutaminase (GLS) and aspartate transaminase (GOT1)dependent mechanism (Son et al. 2013). As PDAC cells require GOT1 for redox homeostasis, it
could be an enticing therapeutic target (Son et al. 2013). Additionally, two previous GLS inhibitors
have shown growth suppressive effect on PDAC cells whose effects are potentiated in the presence
of hydrogen peroxide treatment (Son et al. 2013). Redox homeostasis in PDAC is disrupted by the
inhibition of GOT1 or GLS and maybe effective treatment in combination with chemotherapy and
radiation that increase reactive oxygen species (Lyssiotis et al. 2013).
To gain specificity and selectivity, immunological approaches have been utilized to
differentiate between wild-type and mutant kRAS. Because mutated kRAS can be classified as
being tumor specific, a synthetic peptide technique was used to target cytotoxic T-cells to tumors
expressing the altered protein where p21RAS already underwent membrane localization (Gjertsen
& Gaudernack 1998). This posed some difficulties as T-cells require full activation via multiple
signals, and the kRAS mutation was found to be poorly immunogenic which resulted in ineffective
vaccinations (Fossum et al. 1995; Gjertsen et al. 2001).
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One of the newer approaches includes the effect of transcriptional regulators TAZ/YAP.
Elevated nuclear levels of the transcriptional regulators TAZ and YAP (TAZ/YAP) are associated
with a broad range of aggressive cancers (Harvey et al. 2013). YAP1 allows kRAS-dependent
pancreatic cancer cells to survive even when the oncogenic kRAS is inhibited (Kapoor et al. 2014;
Shao et al. 2014). Moreover, activation of YAP1 and TAZ in acinar cells up-regulate JAK-STAT3
signaling to promote the development of PDAC in mice (Gruber et al. 2016). Mechanistically,
active YAP1 and TAZ interact with the TF TEAD, which binds and up-regulates the expression
of several genes in the JAK–STAT3 pathway. Future studies are warranted for combination
therapy against oncogenic kRAS and YAP1. Recently, targeting mutant kRAS via the small
molecule inhibitors of kRAS-SOS binding pocket has yielded promising results (Wilson & Tolias
2016). Fragment-based screening has been used to synthesize GDP-bound kRAS mutant G12D
compounds (Sun et al. 2012). This interaction with kRAS binding pocket inhibits its downstream
signaling cascade by causing conformation change in protein and preventing kRAS-SOS
interactions. However, further optimization of these compounds is needed to gain the affinity
required to move the compounds into clinical trials. Recently, a series of inhibitors irreversibly
targeting kRAS-G12C by forming a covalent attachment to the mutant cysteine was developed
(Ostrem et al. 2013). These compounds bind in an allosteric pocket beneath switch II, causing
decreased cell viability and increased cell death in lung cancer cell lines harboring the mutation
when compared to cells with wild-type kRAS. Unfortunately, the compounds have a limited
potency to move from preclinical to clinical trials and are not expected to be effective in pancreatic
cancer as 3% of total mutations are G12C in pancreatic cancer. Based on these approaches,
suppressing kRAS expression has shown preclinical promise, but no viable molecular target has
yet been established.
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Our approach is to transcriptionally downregulate kRAS through the stabilization of a nonB-DNA G4 structure in the proximal promoter. The region of the proximal promoter in the kRAS
gene from -324 to -39 bp, in relation to the transcriptional start site (TSS), contains a high density
of guanine residues. The three distinct guanine runs have potential to form multiple G4 isoforms
that can act as silencing elements (Lavrado et al. 2015). These regions are labeled based on their
proximity to the TSS, the near (-129 to -161), mid (-174 to -226), and far (-238 to -273) (Morgan
et al. 2016). Previously, several varying structures have been reported for G4near (Cogoi et al. 2008;
Cogoi & Xodo 2006; Paramasivam et al. 2011; Paramasivam et al. 2009; Cogoi et al. 2009). The
predominant structure was confirmed in Dr. Brooks’ laboratory by Dr. Vanessa Gaerig (data not
shown). Recently, our lab showed kRAS G4mid fold into a G4 structure and act as the
transcriptional silencer (Morgan et al. 2016).
Several G4 stabilizing compounds have been discovered to date (Figure 5-1). Telomere
G4 stabilizing compound telomestatin, BRACO19, and RHSP4 showed antitumor activity in
various xenograft models (Rodriguez et al. 2008; Rahman et al. 2009). SYUIQ-5 inhibits MYC
promoter activity in a cell-free system and two leukemia cell lines (Liu et al. 2007) by acting as a
telomerase inhibitor and inducer of telomere damage (possibly via stabilization of telomeric G4
DNA (Zhou et al. 2009). The telomestatin derivative S2T1-6OTD showed selectivity to MYC G4
structure and was shown to reduce the expression of MYC and TERT in childhood
medulloblastoma and atypical teratoid–rhabdoid tumor cells (Shalaby et al. 2010). Trisubstituted
isoalloxazines that bind to and stabilize the G4s formed by KIT1 and KIT2 reduce KIT transcript
levels in cells that express KIT (Bejugam et al. 2007). Previous studies have looked at compounds
that stabilize kRAS G4near, such as guanidine phthalocyanines (DIGP and Zn-DIGP) and 7carboxylate indolo[3,2-b]quinoline tri-alkylamine derivatives (IQ3A) (Brito et al. 2015; Cogoi et
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al. 2010). Recently, compound benzophenanthridine alkaloid stabilizes the three existing kRAS
G4s and led to downregulation of gene expression (Kaiser et al. 2017).
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Figure 5-1. Interaction and effect of G4-interacting compounds in promoter of genes.
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Pancreatic cancer is projected to become the third leading cause of cancer deaths surpassing
breast cancer in the U.S. in 2016 (Siegel et al. 2016), and the second leading cause of cancer deaths
in the U.S. by around 2020 (Rahib et al. 2014). Less transcription will lead to less translation of
kRAS protein, and thus will affect the downstream signaling pathways associated with it which
will finally cease the growth of the tumor. In the current work, we seek to identify and characterize
compounds that bind and stabilize the G4 structure in the mid region of the kRAS, classifying
them as G4mid and G4near stabilizers and to examine the mechanism of action of such agents in
pancreatic cancer cells.
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5.2. kRAS promoter G4 stabilization
We characterized compounds submitted by our collaborator, Dr. Khondaker Miraz
Rahman from King’s College in London. We were evaluating the compounds for selectivity to G4
structures within the kRAS promoter, specifically the mid region. Two different classes of
compounds were analyzed. The BF series, (Figure 5-2A) a biphenylene and bipyridine connected
bis-benzofuran, consisted of 12 compounds designed with the help of molecular modeling to
facilitate interaction with G4 sequences. Tertiary amine side chains were incorporated to the C2position of the benzofuran ring to improve the DNA binding affinity. The KN series is a tri-aryl
benzofuran (Figure 5-2B) class of compounds, designed to interact with G4 sequences. As with
the BF series, tertiary amines were incorporated at the C2-position of the benzofuran ring to
improve DNA binding. 35 novel compounds were screened for their ability to stabilize G4
structures in the kRAS promoter, and to downregulate kRAS promoter activity. Thermodynamic
stability and compound selectivity were examined for G4mid and G4near upon compound addition
(Table 1). In the BF series, four compounds markedly increased G4mid stability over G4near: BF1.3, -2.2, -3.3, and -4.2 (Figure 5-3A). Within the KN series, six compounds - KN-119, -159, 212, -239, -257, and -267, showed stabilization of G4mid over G4near, and seven compounds
recognized and stabilized both G4s (KN-154, -217, -232, -237, -242, -247, and -272 (ECD
performed by Dr. Rhianna M. Morgan, Figure 5-3B.) Further, the compounds were tested for their
effect on kRAS promoter activity in the HEK-293 cells.
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Figure 5-2. Basic structure of KN (A) and BF series compounds (B).
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Figure 5-3. kRAS promoter G4 stabilization. 35 compounds of two different series (BF &KN)
were screened by ECD to examine changes in thermal stability of G4mid and G4near (A). In BF
series 4 compounds markedly increased G4mid stability over G4near. On the other hand, for KN
series 13 compounds markedly increased G4mid melting temperature compared to control while 7
increased that of G4near (B). Black box represent TM mid and white boxes represent TM near.
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5.3. Changes in kRAS promoter activity
HEK-293 cells were transfected with a luciferase plasmid driven by the kRAS promoter
(Morgan et al. 2016) and were treated with 1 µM of each BF and KN compound for 48 hr. BF-1.2,
-2.2, -2.3, -4.2, -4.3, -5.3, and -6.3 significantly downregulated promoter activity in the kRAS
plasmid (FL), as compared to EV negative control and DMSO-treated cells (Figure 5-4A). For the
KN series of compounds, KN-89, -157, -159, -160, -161, -212, -237, -239, -242, and -272
significantly downregulated kRAS promoter activity (Figure 5-4B). Considering both the
thermodynamic stability profile (for both promoter G4s) and the compounds’ effects on promoter
activity, BF-1.2, -2.2, -2.3, -4.2, -4.3, -5.3, and -6.3 the compounds of the BF series and 5
compounds of KN series KN-159, -212, -237, -239, -242, and -272 were selected for further studies
in the pancreatic cancer cell line panel. BF 1.3, -3.3, and -6.2 were the negative control as they had
no significant effect on promoter activity but affected the G4mid stability profile.
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Figure 5-4. Changes in kRAS promoter activity. BF & KN compounds modulate kRAS
promoter activity. HEK-293 cells were transfected with a luciferase plasmid driven by the kRAS
promoter and were treated with 1 mM of each BF & KN compound for 48 hr. For BF series 7
compounds significantly downregulated kRAS promoter activity (A). Whereas for KN compounds
10 compounds led to this decrease (B). Experiments were run minimally in triplicate, with
technical duplicates; Red bars, *p< 0.05 versus control).
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5.4. Compound gene regulation and G4 stabilization
Two-thirds of the BF series compounds only showed inhibition of cell viability at 100 µM
after 72 hr exposure. Only three compounds – BF-2.3, -4.3, and -5.3 were selected for further
studies in pancreatic cancer cell lines at 30 and 100 µM based on their cytotoxicity profile. BF-6.3
was selected as a negative control. We wanted to take into account the effects of these compounds
on cell lines with different levels of kRAS addiction, so the compounds were tested in both Panc1 and MiaPaCa-2 cell lines. Panc-1 is less addicted to kRAS than MiaPaCa-2 cells (Aoki et al.
1997). We sought to correlate a decrease in cell viability with a decrease in kRAS transcription by
determining each compounds’ influence on kRAS mRNA expression. None of the BF series of
compounds downregulated kRAS mRNA expression; rather, BF-5.3 and -6.3 lead to significant
increase in kRAS mRNA levels in Panc-1 cell lines (Figure 5-5A) and BF-4.3 and -5.3 showed a
significant increase in kRAS mRNA levels in MiaPaCa-2 cell line (Figure 5-5B). The mechanism
behind such an increase is unknown.
Within the KN series of compounds, only KN-242 and -272 demonstrated a dosedependent cytotoxic effect on pancreatic cancer cells. KN-242 had IC50 values of 2 and 11 μM in
Panc-1 and MiaPaCa-2 cells, respectively (Figure 5-6A) and KN-272 had IC50 values of 60 and 6
μM in Panc-1 and MiaPaCa-2 pancreatic cancer cells, respectively (cell viability with KN-272
treatment performed by Dr. Rhianna Morgan, results not shown).
KN-272 had no marked impact on kRAS mRNA expression in MiaPaCa-2, compared to
untreated cells (KN-272 RT-qPCR performed by Dr. Rhianna M. Morgan, results not shown). KN242 significantly reduced kRAS expression Panc-1 and MiaPaCa-2 cells at a dose correlating with
inhibition of cellular viability. In an effort to examine G4-selectivity, the transcriptional regulation
of other genes (MYC, Bcl-2, and ADAM-15) with biologically active promoter G4s was measured
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(Siddiqui-Jain et al. 2002; Dexheimer et al. 2006; Brown et al. 2013). KN-242 also affected the
expression levels of MYC and Bcl-2 but had no effect on ADAM-15 in Panc-1 cells. On the other
hand, in MiaPaCa-2 cells, KN-242 altered the expression of all three genes. (Figure 5-6C).
Overall, after the characterization of 35 novel compounds, KN-242 was identified as a lead
compound to be further characterized for its selectivity for kRAS, its ability to distinguish DNA
structures (G4 vs dsDNA) and a determination of its mechanism of action.
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Figure 5-5. Changes in kRAS gene regulation. (A) Cytotoxicity of BF series of compounds. The
dose-dependent effects of the pyridine series of BF compounds was examined following 72 hr of
treatment in MiaPaCa-2 (B) and Panc-1 (C) cell lines. No significant decrease in mRNA was noted
with any compound. Experiments were run minimally in triplicate with technical duplicates used
for qPCR; *p<0.05 indicates a significant increase in expression, as compared to untreated
controls. These findings indicate that there is a different mechanism of action of decreased cell
viability in vitro than expected.
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Figure 5-6. KN-242 cancer gene regulation & G4 stabilization. (A) Cytotoxicity of KN-242
on Panc-1 (IC50 = 2 µM) and MiaPaCa-2 (IC50= 11 µM) cells. (B) SVD for KN-242 in kRAS mid
and MYC with KN-242, which stabilizes kRAS mid and MYC G4 by 33 and 40°C, respectively.
(C) The effect of KN-242 on endogenous promoter activity was evaluated by qPCR. KN-242
decreased kRAS expression by nearly 30% in both MiaPaCa-2 and Panc-1 cells. MYC expression
was also decreased by 40% in both cell lines. *p<0.05, 2-tailed student t-test versus untreated
control.
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5.5. Discussion
In the current work, we examined 35 compounds from two pharmacophore series developed based
on molecular modeling. These compounds were screened against two G4s within the kRAS
promoter, and after thermodynamic stability validation using ECD, nine compounds (four for BF
series and five for the KN series) stabilized G4mid only, and seven compounds from the KN series
stabilized both G4mid and G4near. These compounds were further filtered based on the luciferase
assay, cytotoxicity profiles, and qPCR results. We were able to identify a lead compound, KN242, which showed a significant effect on kRAS expression, as well as several other oncogenes
involved in tumorigenesis. These G4 stabilizing compounds typically lack selectivity with a
particular G4 structure as they have tendency of ubiquitously binding to all G4 structures; future
development efforts will involve increasing selectivity of this compound for the target promoter
G4 structures through variations in side chains and halogen group replacements. Additionally,
compounds already synthesized and future analogs will be screened against other biologically
active G4s such as MYC, VEGF, Bcl-2, c-kit, hTERT, and ADAM-15 (Morgan & Brooks 2016).
Previously, the G4-forming region within the kRAS promoter has been examined for its
effects on kRAS regulation. This has been performed through the use of protein transfection and
G4-decoys that differ from G4s structurally based on locked or twisting base modifications. In
each of these instances, treating cells with decoys of the G4near led to transcriptional silencing,
putatively by sequestering G4-destabilizing proteins that normally unfolded chromosomal
structures (Cogoi et al. 2008; Paramasivam et al. 2009; Cogoi et al. 2010). Previous studies have
also looked at small molecules targeting kRAS G4near and G4mid. Guanidine phthalocyanines such
as DIGP and Zn-DIGP stabilize G4near and this interaction led to increase in kRAS transcription
(Cogoi et al. 2010). On the other hand, in kRAS-dependent colon cancer cell lines, 7-carboxylate
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indolo[3,2-b]quinoline tri-alkylamine derivatives (IQ3A) down-regulates kRAS expression, by
stabilizing G4near (Brito et al. 2015). Compound benzophenanthridine alkaloid stabilizes the three
existing kRAS G4s and led to downregulation of gene expression (Kaiser et al. 2017).
Recently it was described by our group that the silencing effect of G4s within the promoter
of kRAS is seemingly contained in the mid region from -226 to -174, relative to the TSS, whereas
G4near had no discernible effect on kRAS transcription (Morgan et al. 2016). These studies indicate
that the G4mid is a more optimal target to modulate kRAS expression, a therapeutic approach which
has been validated to have anti-cancer efficacy (Gray et al. 1993; Zhang et al. 1993; Aoki et al.
1997). Therapies targeting mutant RAS protein GTP binding, protein localization or downstream
signaling pathways have failed to yield clinical agents related to mutant RAS activity (Ghobrial &
Adjei 2002; Adjei 2001; Cho & Lee 2002; Queneau et al. 2001; Rowinsky et al. 1999; End 1999).
Drugging the ‘undruggable’ kRAS requires a new approach, such as stabilization of unique DNA
structures. Our approach of targeting G4 structures in the kRAS promoter for transcriptional
silencing will halt all the downstream pathways associated with kRAS and ultimately lead to
cancer cell death. Cumulatively, this information could positively impact the ongoing research
related to the development of new chemotherapeutic agents for downregulating kRAS
transcription against pancreatic cancer.
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CHAPTER 6. CONCLUSION
This work looked at the regulation of kRAS promoter at the transcriptional level, and by
small compound modulation. Our regulation focus was on TFs, their interactions with DNA
regions and topologies, and their biological effects on kRAS transcription. Characterization of the
promoter region and its regulatory proteins is important to understand the transcriptional regulation
of any gene. We classified TFs as both transcriptional activators and silencers of kRAS, filling a
knowledge gap in kRAS regulation. We identified seven proteins and evaluated their biological
effects on kRAS transcription. We also identified two proteins (E2F-1 and nucleolin) which affect
the stability of kRAS promoter G4 structures. Further, as described below, we looked at
modulating these G4s with small molecules to regulate transcription.
We looked into the TFs that were previously reported in the literature, as well as others
identified by their putative binding consensus sequence from the PROMO database. In addition,
we identified TFs by direct binding studies. Overall, we explored the function of seven TFs. The
kRAS basic promoter extends from -510bp to + 50bp (Jordano et al. 1986; Jordano et al. 1988;
Yamamoto et al. 1988). Our lab demonstrated that transcriptional activity was contained from 324 to + 50bp (Morgan et al. 2016); therefore, for our future work we utilized the -324 to + 50 bp
plasmid. Previously, it was shown that core promoter region from 0 ±50 bp plays a critical role in
transcription initiation and guiding and that the upstream region is necessary for full expression.
The upstream region contains three putative G4-forming regions, two of which form stable
structures (G4near and G4mid) (Cogoi et al. 2013; Morgan et al. 2016). Cumulatively, we
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examined MAZ, Sp1, E2F-1 AP-2, PPAR-γ, YBX-1, and nucleolin for their effects and function,
binding and G4-interactivity.
Of these, only TF examined previously was MAZ. By EMSA and filter binding assay MAZ
was shown to bind to the G4near kRAS promoter and this binding led to MAZ sequestration and
effects the kRAS transcription (Cogoi et al. 2010; Cogoi et al. 2013; Cogoi et al. 2014). Our finding
here contradicts the work done by Cogoi group, in which they showed MAZ binding to near G4
and duplex kRAS and this interaction leads to 3.5 fold increase in kRAS transcriptional activity in
Panc-1 cell lines (Cogoi et al. 2013). We accomplished our studies by a step-by-step approach,
starting from the basic level to minimize the variables in our studies. We first focused on the effect
of MAZ in an isolated system of non-cancerous cell lines (HEK-293), such as less noise or
variation due to other factors as present in cancerous cells. Secondly, we took in account broader
panel of pancreatic cancer cell lines based on their kRAS addiction pattern, and we also calculated
the level of these proteins at basal levels in cell lines which are not accounted for in previous
studies. Further, we confirmed RT-qPCR transcriptional downregulation by western blotting and
found similar results showing reduce kRAS protein levels in these cell lines at 500 ng of MAZ
plasmids. Sp1 interacts with the TATA-less promoter and is shown to interact with hRAS. Sp1
was also identified in our PROMO database search. E2F-1 was our third hit which showed four
binding sites in core promoter region. After identifying these hits, our aim was to examine TF
mediated regulation of the kRAS promoter and to understand their biological role.
We decided on a two-step approach. The first approach was to test these TFs in simplified
promoter system using non-cancerous cell line. We performed the luciferase assay in HEK-293
cells with the plasmid containing the kRAS promoter from -324 to +50 bp relative to the TSS. We
found out that MAZ and Sp1 downregulate kRAS promoter when used individually, but in
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combination, the effects were abrogated, leading to an increased kRAS promoter activity. On the
other hand, E2F-1 increased kRAS promoter activity. The second approach was to overexpress
these proteins in pancreatic cancer cells, i.e., Panc-1, MiaPaCa-2, and AsPc-1 and to study the
effects in a multicellular mileu. We also examined an important protein kinase CK2 shown to
phosphorylate these proteins and alter the binding of these proteins to DNA. The result was
surprising as AsPc-1 cells showed a significant increase with CK2 inhibitor TBB treatment while
Panc-1 and MiaPaCa-2 showed a significant decrease. Future studies are warranted to look into
the mechanism leading to such variation.
Lastly, we examined the binding of these proteins on different regions and topologies in
the kRAS promoter. We also tested all these proteins to determine their effect on G4 stability by
ECD. We found that out of three proteins only E2F-1 significantly destabilized the kRAS G4near.
We further wanted to evaluate the global binding and regulation of kRAS promoter. The
three-way approach was utilized to identify and characterize different regulatory proteins binding
to the kRAS promoter. These included rVISTA genome tool (Zombon et al. 2005), Promoter
Binding TF Profiling Plate Array kit (Signosis, Santa Clara, CA) and DNA pulldown assay
followed by LC-MS/MS for protein identification (Wu 2006). After filtering out, the data were
selected for subsequent biological investigation.
These selected proteins underwent the same biological evaluation as mentioned in chapter
3. Over time, the increased AP-2, PPAR-γ, and nucleolin expression led to an increase in kRAS
promoter activity as measured by luciferase expression. Our fourth hit YBX-1 however, showed a
significant decrease in the promoter activity. Ultimately from luciferase data, we classified the
identified proteins in two categories as promoter activators (AP-2, PPAR-γ, and nucleolin) and
promoter silencers (YBX-1). Whereas after comparing the result obtained from endogenous
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regulation through RT-qPCR, PPAR-γ and nucleolin (500ng) were classified as the transcriptional
activators as they caused an increase in kRAS promoter activity and increased % mRNA
expression. On the other hand, AP-2 and YBX-1 showed opposite effect in luciferase assay and
RT-qPCR, so further investigation is required for their classification. Finally, these proteins were
tested for their binding profiles using EMSA and were further analyzed for their effects to G4
stabilization by ECD. Nucleolin was the only hit obtained with a significant destabilization of the
kRAS G4mid structure. Previously it was shown that nucleolin stabilizes MYC G4 structures and
by doing so, it led to decrease in MYC transcription. However, for kRAS promoter results obtained
were opposite. Future work is required to understand the role of two G4 interacting proteins
identified in our studies i.e., E2F-1 and nucleolin. With CHIP-seq, binding to the specific DNA
sequence will be evaluated. E2F-1 and nucleolin will be tested for their role in folding or unfolding
of structures, and by DMS foot printing, the guanines involved in destabilizing the structure will
be studied. As these two proteins lead to an increase in kRAS transcription, they can also be used
as a drug target by small molecules to prevent their binding to the kRAS promoter or by using the
G4 stabilizing compounds to prevent the disruption of G4 stability by these proteins. Moreover,
the other TFs which were detected in our methods such as NME1, YBX-3, Nucleophosmin, BTF3,
LYRIC, hnRNPs, 14-3-3s, IGFs, STATs, NFAT, and GATA need to be evaluated to complete the
puzzle of kRAS transcriptional regulation.
In addition to understanding the molecular basis of kRAS regulation, we also focused on
finding new drug targets against this oncogene. kRAS is one of the highly deregulated oncogenes
that promotes tumorigenesis. In 30% of all cancers and 90% of PDAC, kRAS is mutated (Ryan et
al. 2014). Several approaches have been utilized to target kRAS with little to no success. These
six promising paths include- direct inhibitors of kRAS, disturbing its membrane association,
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synthetic lethal interactors, the kRAS downstream inhibitors, targeting kRAS metabolic regulatory
processes, and harnessing the immune response (Ghobrial & Adjei 2002; Adjei 2001; Cho & Lee
2002; Queneau et al. 2001; Rowinsky et al. 1999; End 1999). Targeting kRAS transcriptionally
through G4 stabilization with small molecule has not been used before. We screened 35 novel
compounds for their ability to stabilize G4 structures in the kRAS promoter and downregulate
kRAS promoter activity. Of all those compounds, KN-242 was a hit compound. KN-242
significantly reduced kRAS expression, as well as the expression of other important genes
involved in tumorigeneses, such as MYC, ADAM-15, and Bcl-2. As KN-242 is not specific as a
target, future work is warranted to develop more specific and selective analogs of G4mid and to
further screen libraries to find compounds against other oncogenes in which G4 structure has been
established. Ultimately, G4-stabilization-mediated downregulation of kRAS has a high potential
for anti-cancer efficacy in pancreatic cancers, wherein there is a dire need for novel therapeutic
development.
There is currently a gap in the knowledge regarding the TFs binding to the kRAS promoter,
particularly to varying DNA topologies, and their role in kRAS expression. We focused on several
TFs and classified them as activators and silencers; some of these worked through G4 while others
had no effect on G4 stability profile. Understanding the mechanism of action and combinatorial
effects of TFs is an important part of the larger puzzle leading to a targeted drug discovery program
focused on G4-regulation and utilizing TFs as drug targets themselves. In conclusion, this
information will positively impact the ongoing research related to the development of new
chemotherapeutic agents for downregulating kRAS transcription by unveiling the mechanism of
transcription control and to confirm the mechanism of action of developed compounds.
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